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ABSTRACT
Gene-directed enzyme prodrug therapy is a form of cancer therapy in which
delivery of a gene that encodes an enzyme is able to convert a prodrug, a
pharmacologically inactive molecule, into a potent cytotoxin. Currently delivery of
gene and prodrug is a two-step process. Here, we propose a one-step method
using polymer nanocarriers to deliver prodrug, gene and cytotoxic drug
simultaneously to malignant cells. Prodrugs acyclovir, ganciclovir and 5doxifluridine were used to directly to initiate ring-RSHQLQJ SRO\PHUL]DWLRQ RI İcaprolactone, forming a hydrophobic prodrug-WDJJHGSRO\ İ-caprolactone) which
was further grafted with hydrophilic polymers (methoxy poly(ethylene glycol),
chitosan or polyethylenemine) to form amphiphilic copolymers for micelle
formation. Successful synthesis of copolymers and micelle formation was
confirmed by standard analytical means. Conversion of prodrugs to their cytotoxic
forms was analyzed by both two-step and one-step means i.e. by first delivering
gene plasmid into cell line HT29 and then challenging the cells with the prodrugtagged micelle carriers and secondly by complexing gene plasmid onto micelle
nanocarriers and delivery gene and prodrug simultaneously to parental HT29
cells. Anticancer effectiveness of prodrug-tagged micelles was further enhanced
by encapsulating chemotherapy drugs doxorubicin or SN-38. Viability of colon
cancer cell line HT29 was significantly reduced. Furthermore, in an effort to
develop a stealth and targeted carrier, CD47-streptaidin fusion protein was
attached onto the micelle surface utilizing biotin-streptavidin affinity. CD47, a
marker of self on the red blood cell surface, was used for its antiphagocytic
efficacy micelles bound with CD47 showed antiphagocytic efficacy when exposed
to J774A.1 macrophages. Since CD47 is not only an antiphagocytic ligand but
also an integrin associated protein, it was used to target integrin Įvȕ3, which is
overexpressed on tumor-activated neovascular endothelial cells. Results showed
that CD47-tagged micelles had enhanced uptake when treated to PC3 cells
which have high expression of Įvȕ3. The synthesized multifunctional polymeric

XIV

micelle carriers developed could offer a new platform for an innovative cancer
therapy regime.

XV

CHAPTER 1: INTRODUCTION1
1.1.

GENE-DIRECTED ENZYME PRODRUG THERAPY (GDEPT)

Gene therapy, is the insertion of genetic material into an individual’s cell to treat
a disease. The development of gene therapy began during the 1960’s to early
1970’s. During this time, two discoveries were made which helped establish gene
therapy as a therapeutic approach—an efficient method of gene transfer and
cloned forms of specific genes. The first clinical gene therapy protocol was
approved in 1989 and since then, more than 1800 clinical trials have been
approved world-wide, more than 60% for treatment of cancer (Figure 1.1) [1, 2].
0.70% 2.40%

1.60%
1.80%
7.80%

Cancer diseases

1.80% 2.60%

Monogenic diseases
Infectious diseases

8.20%
9.10%

Cardiovascular diseases

64.10%

Neurological diseases
Ocular diseases
Inflammatory diseases
Other diseases
Gene marking
Healthy volunteers

Figure 1.1. Graphical representation of the different indications addressed by gene
therapy clinical trials. Adapted from The Journal of Gene Medicine, Wiley and Sons
(http://www.abedia.com/wiley/index.html).

Suicide gene therapy or GDEPT, is a form of gene therapy in which genes
are delivered to the targeted cells and expressed. These genes have the ability
to convert inactive molecules (prodrugs) to a toxic species (Figure 1.2). Ideally,
activation of a prodrug occurs by an enzyme that is either expressed in the tumor
1

The material contained in this chapter was previously published in Nanomedicine for
Drug Delivery and Therapeutics Ch. 15, (2013) 438-469, and Therapeutic Delivery 4
(2013) 825-839.
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site in higher concentrations or unique to the tissue. Various combinations of
enzyme and prodrug systems have been proposed for GDEPT, these include
classical suicide gene/prodrug combinations such as cytosine deaminase/ 5fluorocytosine, cytochrome P450/ cyclophosphamide, thymidine phosphorylase/
5-doxifluridine, and the most well studied strategy herpes simplex virus thymidine
kinase/ganciclovir [3, 4].
1.1.1. Prodrugs for thymidine kinase (TK)

Figure 1.2. Gene Directed Enzyme Prodrug Therapy. Current two-step delivery of
gene and prodrug for the treatment of cancer. First, the activation enzyme is
delivered and expressed in the cell. Second, the prodrug is administered and
activated to its cytotoxic form by the enzyme, leading to cell death.

The most prominent and well-studied enzyme/prodrug GDEPT therapy is the use
of herpes simplex virus thymidine kinase (HSV-TK) in conjunction with a variety
of guanosine-based prodrugs i.e. ganciclovir (GCV), penciclovir, acyclovir (ACV),
valacyclovir,

(E)-5-(2-bromovinyl)-2’-deoxyuridine,

and

2’-exo-methano-

carbathymidine [4]. Here, HSV-TK enzyme converts the prodrugs to their
monophosphate, other cellular kinases (such as cellular guanylate kinase and
cellular phosphoglycerate kinase) then convert the monophosphorylated form of
the prodrug to the toxic triphosphate. Cell death is caused by inhibition of DNA
2

polymerase by the incorporation of dGTP into elongating DNA during cell division
[5, 6]. However, prodrugs of HSV-TK are dependent upon the ‘bystander effect’
for enhanced infectivity. The bystander effect for HTV-TK system was first
described in 1990 by Moolten and Wells [7]. These experiments showed that
even if only 10% of cells were transfected with HTV-TK gene plasmid, treatment
with GCV could lead to 100% cell death. Several mechanisms for the bystander
effect have been proposed, including: apoptosis, and gap junctions [8, 9]. The
most accepted mechanism of the bystander effect is that the transfer of toxic
metabolic products happens through gap junction intercellular communication
(GJIC) [8, 10-13]. Cells and tissues use gap junctions to pass information from
one cell to the next through channels. These channels are formed from two
oligometric integral membrane proteins called connexons. Connexons regulate
intracellular transfer of metabolites as well as ions [14]. It should be noted that in
studies where GJIC was inhibited, the bystander effect was still observed [12,
15]. Therefore, it is commonly agreed that bystander cell death is due to multiple
combinations of cellular mechanisms.
1.1.2. Prodrugs for thymidine phosphorylase (TP)
TP is an endogenous enzyme reported to occur to a greater extent in tumor cells
than in normal tissue. Furthermore, TP is an angiogenic factor meaning the
upregulation of TP in cells has the potential for enhanced tumor growth. 5deoxyfluoridine (5’DFUR) is an analog of deoxyuridine and a prodrug of 5fluorouracil (5-FU). 5’DFUR is converted to its active and toxic form, 5-FU,
through cleavage by TP. TP expression in some breast, ovarian, colorectal and
gastric cancers is upregulated and therefore direct use of 5’DFUR has been
researched [16-18]. Similar to the HSV-TK system, TP/5’DFUR exhibits a strong
bystander effect [17]. Here, it has been shown that the bystander effect for the
TP/5’DFUR system does not to require cell-cell contact [19] significantly
enhancing TP/5’DFUR as a suicide gene pair.
3

1.2.

CURRENT POSITION OF GENE THERAPY

Despite the current successes with gene therapy, there are genuine concerns
regarding the safety of gene transfer in humans as well as technical issues in
terms of quality and stability of transgene expression; most notably, is the use of
viral vectors for delivery of genes into host cells. In 1999, gene therapy was
delivered a blow when 18-year old Jesse Gelsinger took part in a gene therapy
clinical trial at the University of Pennsylvania in Philadelphia. He was
administered a high

dose of

adenovirus for treatment of

ornithine-

transcarbamylase. His immune system responded immediately and four days
later he died due to multiorgan failure [20]. Markedly, this was the first known
case in which a death could be directly linked to the viral vector used for the
treatment. Despite the setback from Gelsinger’s death, gene therapy is still a
promising tool for cancer therapy. As such, several gene therapy products have
made their way into the clinical setting outside of the United States.
Since 2000, several gene therapy based products have been approved for
clinical use including GendicineTM and OncorineTM which received approval in
China in 2003 and 2005, respectively. GendicineTM, developed by SiBiono Gene
Tech Co., is an adenoviral vector in which E1 gene is replaced with a human p53
cDNA for treatment of head and neck squamous cell carcinoma [21, 22].
OncorineTM, developed by Sunway Biotech Co. Ltd, contains a deletion in the
E1B 55k region which restricts virus binding to p53 protein and is approved for
use in combination with chemotherapy [23]. In 2004, Ark Therapeutics Group plc,
obtained a GMP Certification in the European Union for the manufacture of genebased medicine, Cerepro® [24]. Cerepro®, is an adenoviral vector which carriers
the gene for HSV-TK and is intended for the treatment of malignant brain tumors
through GDEPT. In 2008, Cerepro® became the first and so far the only
andenoviral vector to complete a phase III clinical trial [25, 26]. Most recently, in
October, 2012, the European Commission granted marketing authorization for
Glybera® for treatment of severe lipoprotein lipase deficiency [27].
4

It should be noted that these gene therapy products still employ viral vectors
for their delivery. As noted by the death of Jesse Gelsinger, viral vector delivery
is notorious for causing immunogenicity and tumorigenicity. Therefore, the use of
nonviral delivery methods can and are explored for cancer gene therapy.
1.3.

NONVIRAL DELIVERY METHODS

Incorporation of chemotherapeutic agents into nanoparticle-based drug delivery
systems such as, liposomes, polymeric nanoparticles, microcapsules and
micelles have been studied extensively for the delivery of drugs to treat a wide
range of cancers [28-31]. Due to the fact that nanoparticles can be prepared using
a variety of polymers, biodegradable polymers have been studied extensively.
Moreover, considerable research has been conducted in the preparation of a
variety of biodegradable polymeric nanoparticles for drug delivery [29, 32-35]. For
these reasons, polymeric nanocarriers are a choice delivery system for cancer
gene therapy.
In particular, polymeric micelles have shown promise for their use in cancer
treatment. Polymeric micelles can be prepared using a variety of biodegradable
and FDA approved polymers [36, 37], which can house hydrophobic drugs
enhancing bioavailability [38]. In addition, polymeric micelles possess a small
size (< 200 nm) which allow them to passively target tumor cells through the
enhanced permeability and retention (EPR) effect [39]. Both in the laboratory and
clinically polymeric micelles are proving effective for cancer treatment [40].
Currently, six micellar systems have made their way into clinical trials. NK105,
and Genexol-PM are miceller formulations used for the encapsulation of
paclitaxel (PTX). PTX is known to be useful combating ovarian, breast and lung
cancers [41, 42]. PTX however has very serious side effects such as neutropenia
and peripheral sensory neuropathy. In addition, due to the mixture of Cremophor
EL and ethanol used to solubilize PTX, 2-4% of patients report anaphylaxis and
5

other severe hypersensitive reactions [43]. NC6004 is a poly(ethylene glycol)
(PEG) based polymeric micelle for the entrapment of cisplatin. Cisplatin (cisdichlorodiammineplatinum[II] or CDDP) is commonly used to treat epithelial
malignancies of the lung, ovarian, bladder, testis, head and neck, esophagus,
gastric, colon and pancreas. However, similar to PTX, CDDP causes several
serious adverse side effects such as nephrotoxicity and neurotoxicity, which lead
to discontinued treatment [44]. Despite the development of platinum analogues
(e.g. carboplatin and oxaliplatin) [45] to overcome CDDP related disadvantages,
CDDP has higher toxicity and is the standard treatment for cancer therapy [46,
47]. NC6004 was developed to reduce side effects associated to CDDP and to
improve efficacy of delivery to targeted sites. NK012 is a micelle carrier
composed of PEG-b-poly(glutamic acid) (PGlu), SN-38 (a metabolite of irinotecan
hydrochloride, CPT-11) was conjugated to PGlu by coupling agent 1,3diisoproylcarboiimide and catalyst N-dimethylamino-phridine, causing PGlu to
become more hydrophobic leading to micelle formation [48]. Both SP1049C and
NK911 are micelle carriers developed for the encapsulation of doxorubicin,
another widely used anticancer agent.
1.4.

COMPOSITION,

FORMATION

AND

CHARACTERIZATION

OF

POLYMERIC MICELLES
Interest in using block copolymers for drug delivery has arisen mainly because of
their self-associative characteristics. Block copolymers are macromolecules with
two or more different polymer blocks arranged in a linear and/or radial
arrangement. Synthesis of di- and triblock copolymers has been studied
extensively [49]. Commonly, block and graft copolymers are synthesized by ringopening polymerization [50, 51] or free radical polymerization [52, 53]. Diblock
copolymers have shell and core structures. The hydrophilic shell segment
protects the drug from the aqueous environment and stabilizes the micelle, while
the hydrophobic core encapsulates the non-water soluble drug. In some cases,
the core can be made up of a water soluble polymer caused to be hydrophobic
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by chemical conjugation to a hydrophobic drug [54], or by complexation of two
oppositely charged polyions [55]. In addition to diblock copolymers, multiblock
copolymers i.e. triblock and graft copolymers, have been described as potential
drug carrier systems [56, 57]. Generally, when the hydrophilic segment is longer
than the core block, spherical micelles are formed (Figure 1.3). In contrast, rods
and lamellae form when the length of the core segment is longer than the corona
chain [58]. Choosing an appropriate copolymer system is essential to achieve an
ideal drug carrier and every polymer combination has its own unique advantages.

Figure 1.3. Block-copolymer micelle. A block-copolymer micelle loaded with a
hydrophobic chemotherapeutic agent and functionalized with a target-specific ligand.

1.4.1. Micelle formation
The hydrophobic corona of micellar systems is commonly made up of polyesters,
polyethers and poly(amino acid) derivatives. Commonly used poly (L-amino
acids) include poly(L-aspartate) and poly(L-glutamate). For these polymers to
self-assemble into amphiphilic micelles, they need to be electrostatically neutral
or conjugated to hydrophobic moieties [59]. FDA approved polyesters used in
copolymer synthesis include poly(lactic acid) [60] SRO\ İ-caprolactone) (PCL)
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[61, 62] and poly(glycolic acid) [63, 64]. A triblock copolymer of pharmaceutical
interest belongs to the poloxamer family, Pluronics (BASF Corp) is a copolymer
composed of poly(ethylene glycol)-b-poly(propylene oxide)-b-poly(ethylene
glycol) [65]. Engineering of block copolymers affects the temporal and distribution
controls of the polymeric micelles. Controlled release of the drug (temporal
control) and site-specific delivery (distribution control) can be optimized through
the choice of core and shell polymers.
Routinely, the hydrophilic shell segment is made up of polyethers such as
poly(ethylene glycol) (PEG) [66, 67] and poly(ethylene oxide) (PEO) [68-70].
These polymers are inexpensive, have a low toxicity and serve as efficient steric
protectors of various biologically active macromolecules [70, 71]. The hydrophilic
shell dictates biodistribution of the micelles, and polymers such as poly(Nisopropylacrylamide) [52, 53] and poly(L-lactic acid) [72] impart temperature or
pH-sensitivity to the polymeric micelle carrier. Natural polymers such as chitosan
[73, 74] and dextran [75, 76] have also been employed as hydrophilic shell
polymers due to the nontoxic and antimicrobial effects they can impart on the
carrier. A list of hydrophobic and hydrophilic polymers used in micellar formation
are given in Table 1.1.
Table 1.1. Polymers used in the synthesis of block-copolymer micelles for drug delivery
Hydrophobic (Core Forming) Segment
O
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O
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N
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H
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N

x
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O
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COOH
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n
CH3
O
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n

O
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CH3
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HO
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HO
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O O
OH
HO
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O

OH
OH
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OH
OH
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m

Poly(N-isopropyl
acrylamide)

PNIPAM,

n
O

NIPAM

N
H

1.4.2. Preparation of micelles
There are various techniques used for the self-assembly of polymers into micellar
structures. Selection of appropriate preparation technique is largely based on the
solubility of copolymer and drug solution. These methods are direct dissolution
method, evaporation method and nanoprecipitation/dialysis method (Figure 1.4).

Figure 1.4. Techniques used for the preparation of polymeric micelles. (A) Direct
Dissolution method: drug and copolymer are dissolved in water. (B) Evaporation
method: drug and polymer are dissolved in an organic solvent, solvent is removed
and polymer + drug are re-suspended in an aqueous solvent. (C) Dialysis method:
drug and polymer are dissolved in an organic solvent that is miscible with water,
the solvent mixture is slowly added to the water and then the solvent is removed
by solvent-evaporation method or dialysis.
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Direct dissolution involves dissolving the block copolymer along with the
drug in an aqueous solvent [77]. In contrast, the evaporation method is used for
drugs and copolymers with limited water solubility [78]. The most commonly used
method for the preparation of micellar carriers is the dialysis method which
requires two steps. First, the amphiphilic copolymer and drug are dissolved in an
organic solvent (acetone, ethanol or methanol) both have an affinity toward [79].
Micelle formation then proceeds by a solvent-evaporation method [80]. There are
various types of solvent-evaporation methods. If the copolymer mixture is slightly
water-soluble, it can be dialyzed against water to slowly remove the organic
phase and trigger micellization [81]. The oil-in-water emulsion process both drug
and polymer are dissolved in a water-miscible organic solvent such as
tetrahydrofuran [82] or acetone [83]. This solution is slowly added to water under
vigorous stirring/sonication, rearranging the polymer to form micelles. Micelle
preparation varies with copolymer composition. Vangeyte et al. demonstrated
that the dialysis procedure alone did not offer adequate size control of PEG-bPCL micelles, where as stable assembles were formed by first dissolving the
polymer in an organic solvent and then dialyzing against water [84].
1.4.3. Factors affecting drug loading and drug release from polymeric micelles
Drug loading into the micelle cores is achieved through either chemical
conjugation or physical entrapment. Drug loading efficiency is calculated using
the Flory-Huggins equation [85]. The partition coefficient (Kv) is used to calculate
the extent to which a drug selectively partitions into the micelle core. The
partitioning behavior of drugs in the core controls the amount of drug that can be
solublized in block copolymer micelle carriers. Drug loading efficiency is
dependent on many factors including the size of both the core and coronaforming blocks, specific interaction between the drug and core and the method of
micelle preparation. A larger hydrophobic block leaves a bigger core structure
and therefore increases the ability to entrap the drug [86]. Drug release from
polymeric micelles is dependent on the type of encapsulation process used to
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load the drug. For a chemically conjugated drug, bulk degradation or surface
erosion of the polymer slowly releases the drug. Conversely, for a physically
entrapped drug, diffusion is the main mechanism for drug release. It had been
shown that drugs incorporated into micelles have superior properties compared
to the free drug [87]. Micelles have also been shown to decrease toxicity of a drug
compared to the free form [88]. More recently, prodrugs of doxifluridine (5’-DFUR)
[89] and acyclovir [90] have been used directly in the ring-opening polymerization
RI İ-caprolactone. Our lab has studied the toxicity of 5’-DFUR converted to 5fluorouracil by endogenous thymidine phosphorylase in colorectal cancer cells.
Due to the fact that the prodrug is directly attached to the polymer micelle, another
chemotherapy drug 7-ethyl-10-hydroxy-camptothecin (SN-38) was encapsulated
in the hydrophobic core of the polymeric drug micelle which drastically increased
cell death [91].
1.5.

TARGETING SCHEMES

Development of a good drug delivery system relies heavily on the selection of
appropriate design parameters such as physiochemical limitations of the drug
and/or route of administration. The development of nanoparticles has evolved
substantially over the last few decades and there are several key strategies in
the design of nanoparticles for therapeutic applications [92]. Although there are
quite a few modes of drug administration with their own biological barriers for
drug carriers to overcome, systemic delivery remains the most desired mode
(e.g., treating metastatic cancer where tumor nodules are spread widely around
the body).
Systemic delivery of drug carriers is categorized into two classes: enteral
and parenteral routes. Administration of a drug carrier in the enteral route is
characterized by absorption of the drug through the gastrointestinal tract and
includes oral or rectal administration. In contrast, parenteral drug administration
does not pass through the gastrointestinal tract but is administered directly into
12

the bloodstream. The success of therapeutic carriers is dependent upon the
mode of administration and thereby influences synthesis of the carrier. For
example, oral administration must address carrier stability in the gastrointestinal
tract, whereas intravenous injection must overcome the mononuclear phagocyte
system (MPS) if prolonged blood circulation is desired. Additionally, the carrier
must be designed to specifically target the site for entry [93, 94]. While each
route of delivery has its own pros and cons, intravascular injection due to its
precise and almost immediate onset of action is widely employed for drug
delivery.
Polymeric micelles are required to exhibit a sufficient half-life in the blood
compartment in which solid tumors are normally located outside of. The critical
micelle concentration (CMC) is the concentration at which the single chain
polymers (unimers) begin to associate to from micelles. Polymeric micelles have
a low CMC (10-4-10-7 M). CMC is affected by various properties including size of
core block length. An increase in hydrophobic core length corresponds with a
decrease in the CMC [95]. A longer hydrophobic core is also correlated with
increasing micellar stability [96], increasing in vivo performance. The low CMC of
micelles is advantageous for drug delivery because the carrier will not dissociate
instantly upon intravenous injection to patients.
The size, shape and surface characteristics all play a role in the
biodistribution of particles used for drug delivery. The effect of size and shape on
a particle has been studied extensively [97, 98]. Moreover, it is known that nonbiocompatible nanoparticles are easily recognized by the MPS [99]. Ideal carriers
should be between 10-200 nm to avoid removal by the MPS [98]. If however, the
carrier is larger than 200 nm several strategies have been developed by
researchers to prolong circulation times of particles. The first is to pre-inject decoy
carriers followed by injection of carriers containing therapeutic agents [100]. As a
result, phagocytes of the MPS are saturated with decoy carriers, allowing
therapeutic carriers to escape and reach the desired sites. Secondly, alterations
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to the carrier surface can reduce the rate of protein opsonization or avoid
complement activation.
1.5.1.

Passive targeting

Another key problem for micelle carriers—or any drug carrier is developing an
effective delivery method to and inside tumor cells. Many tumors exhibit a unique
vasculature which possesses hyperpermeability and impaired lymphatic
clearance from the interstitial space. Studies have established a phenomenon in
which long-circulating polymeric carriers can effectively accumulate inside of
solid tumors. The passive accumulation of drugs into tumors is termed the
enhanced permeability and retention (EPR) effect. The EPR effect was first
reported by Matsumura and Maeda in 1986 [101], since then, research into the
EPR effect has grown considerably [39, 102, 103]. Solid tumors, generally
possess a defective vascular architecture, high vascular density and/or active
angiogenesis which can cause enhanced vascular permeability, as a result,
particles ranging from 10-500 nm in size are able to penetrate the endothelial
lining of tumor blood vessels and accumulate inside the interstitial space of
tumors [104]. It is known that extensive production of vascular mediators such as
bradykinin , nitric oxide , vascular permeability factor/vascular endothelial growth
factor, prostaglandin , collagenase and peroxynitrite increase hyperpermeability
of tumor blood vessels and increase the EPR effect [39, 105-111]. For the EPR
effect to be useful in drug delivery, carriers must be long-circulating so that a
sufficient amount of drug can be released into the target cells. One way to
increase blood circulation time is through PEGylation.
PEGylation is the process by which PEG chains are attached to a
molecule or carrier, and the stealth properties of PEG lent to them. Since
PEGylation was first described, several conjugation strategies have been
developed. The variety of modification procedures offered allows for the
PEGylation of a wide variety of carriers and molecules [112]. PEGylated
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dendrimers [113], liposomes [114, 115] and micelles [91, 116] have been
developed as viable therapeutic agents for cancer therapy. Moreover, PEGylation
of chemotherapy drugs [117, 118], protein molecules [119] or monoclonal
antibodies [120], has been employed to increase circulation half-life time and
reduce immunogenicity, without decreasing activity. Chemical conjugation of
adenovirus vectors with PEG has also emerged as a viable strategy to improve
the safety and efficiency of viral gene-delivery vectors [121]. Polymers based on
N-(2-hydroxypropyl)methacrylamide have shown particular promise not only as
drug carriers, but for surface coating of viruses or targeted drug carriers [122,
123]. While PEGylation has improved the pharmacokinetic properties of the
aforementioned systems, overcoming immune clearance and cell entry across
the endothelial lining and into the tissue itself is still something which needs to be
addressed [124]. Furthermore, PEG has several drawbacks such as
hypersensitivity reactions, non-biodegradability, instability under stress and
toxicity of side products [124]. These disadvantages have prompted interest into
the investigation of alternatives to PEG. There have been several alternatives to
PEG suggested which reduce opsonization of drug carriers and increase blood
circulation time [125-127]. Once the cells have reached the tumor site, several
mechanisms have been proposed for the delivery of the drugs into the cells [128130]. Figure 1.5 illustrates a few of the proposed passive targeting mechanisms.
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Figure 1.5. Mechanisms of drug delivery from micelle carriers. (A) Drug is release
from micelle carrier and diffuses into the cell. (B) The micelle carrier disassembles
in extracellular space and the drug is released and diffuses into the cell. (C) Drugloaded micelles are taken up into the cell by endocytosis. The internalized drugloaded micelle reaches the lysosome where the drug is released by either (D)
degradation of polymeric micelles or (E) diffusion.
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1.5.2.

Active targeting

While passive targeting is achieved by exploiting the EPR effect, active targeting
aims to increase drug delivery efficiency by taking advantage of the specific
biological interactions between the tumor cell and carrier. Through conjugation of
a tissue or cell-specific ligand to the carrier system (Figure 1.6), active targeting
has been shown to enhance in vitro cytotoxicity against target cells [131]. Ligands
can target tumor cells in several ways, two of which are through the
neovasculature of angiogenesis and targeting uncontrolled cell growth. Active
targeting also makes use of stimuli sensitivity such as pH and temperature
sensitivity to target increased accumulation of drug into the target tissue.
Kabanov et al. was one of the first groups to apply active targeting on a micellar
GUXJGHOLYHU\V\VWHP7KH\FRQMXJDWHGĮ2-glycoprotein, which targets brain glial
FHOOV WR SOXURQLF PLFHOOHV FRQWDLQLQJ ),7& 7KHLU UHVXOWV VKRZHG WKDW Į2glycoprotein micelles had increased delivery to the brain and decreased
clearance to the lung when compared to non-ligand conjugated pluronic micelles
[132, 133]. Even though many believe active targeting is key for increased
biodistribution, recent reviews suggest that the benefit of active targeting lies not
with in its ability to increase the number of carries to the tumor but with its ability
to facilitate in vivo cellular uptake through passive targeting [134].
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Figure 1.6. Polymeric micelles for targeted drug delivery. Surface modification
allows for site-specific delivery of the drug to the tumor cells through receptormediated endocytosis. (A) Ligand-coupled micelle approaches cancer cells (B)
and bind to the cell surface receptors. (C) The micelles are internalized through
receptor-mediated endocytosis. (D) In early endosomes, the micelle and
receptors undergo sorting where the receptor returns to the cell surface and (E)
then micelles enter the late endosome which later fuses with the lysosome.
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1.5.3.

Receptor-mediated targeting

Cell proliferation markers can be overexpressed on certain tumor cells making
them a good target for cancer therapeutics. Folate, human epidermal and
transferrin receptors are the most commonly used ligand targets for cancer
therapy. These targets are overexpressed in a wide range of tumor cells and their
biological functions as well as internalization pathways have been studied
extensively [135-137]. Ligand-mediated targeting of anticancer drugs to
overexpressed receptors is increasingly becoming an effective strategy for
improving therapeutic effect of cancer drugs [138]. Targeting cell proliferation
receptors exploits tumor’s reliance on continued stimulation by growth factors and
can ensure elimination by stemming the growth of highly malignant tumors and
metastatic cells.
Folic acid is one of the most highly researched targets for cancer therapy
due to the fact that it is an essential vitamin for biosynthesis of nucleotide bases
and is largely consumed by proliferating cells. The receptor for folic acid is
overexpressed on epithelial tumors of various organs such as the colon, lung,
prostate, ovaries, breast and brain [139]. After intercellular transport of folateequipped micelles, the drug is released intracellularly due to the slightly acidic
(pH 5-6) conditions of endosomes. Moreover, folate conjugates have been shown
to escape cancer cells multidrug efflux pumps and remain in recycling
endosomes or escape into the cytoplasm [139]. Folate ligands are nontoxic,
inexpensive, have a high binding affinity (10-10 M), low immunogenicity, can easily
be conjugated to various drug carrier systems and can be stored stably [140].
The human epidermal receptor (HER) family of receptor tyrosine kinases
consists of four closely released receptors. Of these receptor tyrosine kinases
epidermal growth factor receptor (EGFR) and human epidermal receptor-2 (HER2) are known to mediate cell signaling pathways involved in growth and
proliferation in response to the binding of a variety of growth factor ligands [137].
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EGFR is overexpressed in one-third of all solid tumors including breast [141],
lung [142], colorectal [143], head and neck [144], esophageal [145], renal cell
[146], and prostate cancers [147]. There are six known endogenous ligands for
EGFR: EGF, transforming growth factor-Į 7*)-Į  DPSKLUHTXOLQ EHWDFHOOXOLQ
heparin-binding EFG (HB-EFG) and epiregulin [148]. The most commonly
detected in humans and therefore best studied are TGF-Į DQG (*) 7KH
presence of EGFR is frequently associated with metastatic spread [149] however
it has also demonstrated to have pro-angiogenic properties [150]. Targeting
EGFR as an anticancer strategy was first proposed in the 1980’s [151], there are
now 13 anti-EGFR agents undergoing clinical trials either as monotherapy or in
combination with standard treatment [137]. Several EGFR inhibitors mainly
Iressa and Erbitux have even made their way to clinical trials with limited success
[137] and are now FDA-approved [152, 153]. Reilly’s group is now undergoing
phase 1 clinical trials with radiophamaceutical 111In-DTPA-hEGF for treatment of
EGFR-overexpressing breast cancer cells [154].
Transferrin (Tf) is an iron-binding blood plasma glycoprotein that binds to
trasferrin receptors (TfR) which are over expressed in malignant cells due to an
increased iron requirement. Tf binds to endogenous iron in plasma, once bound
to TfR, it is endocytosed into acidic compartments and the bound iron dissociates.
TfRs are overexpressed in certain body tissues such as liver, epidermis, intestinal
epithelium, vascular endothelium of the bran capillary and certain blood cells in
the bone marrow. Tf-TfR mediated drug delivery has been studied for the
treatment of breast cancer, prostate cancer and myeloid leukemia [136, 155,
156]. Use of Tf has been given specific attention with regards to brain cancer
because it can facilitate the transcytosis of drug carriers across the blood brain
barrier. Yue’s group has used active targeting with several targeting moieties
[157, 158]. Recently, the Tf-TfR interaction was studied because of the small
amount of Tf needed to conjugate on the micelle and its higher endocytosis
efficiency. Their results showed that Tf conjugation significantly increased cellular
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uptake of Tf-micelles in MCF-7 and SGC-7901 cell lines. In vivo studies also
confirmed antitumor effectiveness [159].
Angiogenesis is the physiological process involving the growth of new
blood vessels from pre-existing blood vessels. Most mammalian cells retain a
blood vessel size of 100 to 200 μm, to surpass this size, new blood vessels must
be formed [160]. It is known that for a tumor cell to grow beyond its critical size
or metastasize to another organ, new blood vessels must be formed. Therefore,
in 1971, it was proposed that one way to stop tumor growth could be to block
angiogenesis [161]. It is widely accepted that tumor angiogenesis happens by the
activation of the ‘angiogenic switch’. When pro-angiogenic molecules and antiangiogenic molecules are in balance the switch is off but when that balance is
turned, the switch is turned on [162]. There are now more than 30 known
activators and inhibitors of angiogenesis of these, vascular endothelial growth
factor receptors (VEGFR), integrins, matrix metalloproteinase receptors and
vascular cell adhesion molecule-1 are the most common angiogenic targets
studied by nanoscale drug delivery systems [140].
VEGFR is one of the most commonly studied tumor angiogenesis inducers
studied. VEGF ligands bind to and active three different type III receptor tyrosine
kinases: VEGFR-1, VEGFR-2 and VEGFR-3. VEGFR-2 expression is restricted
to the vasculature and therefore has been studied as an inducer of tumor
angiogenesis [163] ,QWHJULQV Įvȕ3 is an arginine-glycine-asparic acid (RGD)
containing molecule that is responsible for anchoring cells to the extracellular
matrix. Several studies have found that Įvȕ3 has a key role in endothelial cell
survival and migration during angiogenesis [164, 165]. In a recent study, PEG-bpoly(lysine) micelles were complexed with cyclic RGD peptide and targeted to
integrin expressing HeLa cells. Uptake of the micelles was viewed by comparing
fluorescently labeled, targeted and untargeted micelles in live-cell imaging
experiments through fluorescence microscopy and flow cytometry. Their results
showed that RGD ligand accelerated the internalization of micelles [166].
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1.6.

ENGINEERING ANTIPHAGOCYTIC BIOMIMETIC DRUG CARRIERS

While synthetic biomaterials for therapeutic delivery have been significantly
advanced in terms of functionality and diversity, they still lack in the complexity
of natural particulates. For example, red blood cells (RBCs) exhibit a complex
biological functionality: they possess a small size, flexibility and chemical
composition which allow them to complete complex tasks flawlessly in the human
body without being recognized as foreign particles for up to 4 months [167].
Pathogens such as bacteria and viruses have developed immune escaping
mechanisms which allow them to infect tissues with maximum efficacy [168].
Recently, researchers’ understanding of immune surveillance has been growing
greatly [169-171] and several immune system components have been implicated
in the identification and elimination of cancer cells [172, 173]. To this end, the
remarkable properties cells in the body possess are being exploited for the
delivery of therapeutic and/or diagnostic agents. Due to the increased
understanding of circulating body cells as carriers, surface biochemistry of blood
cells, and the immune escaping mechanisms pathogens and tumor cells employ,
researchers are taking a lead from nature in the design of drug carriers. Aided by
advances in nanotechnology and biology, researchers are able to design delivery
vehicles which mimic natural cells. These novel biomimetic strategies have been
proposed to camouflage drug carriers in order to bypass immune surveillance.
These systems prolong the circulation time in bloodstream and lead to effective
delivery of theranostic agents.
1.6.1.

Erythrocyte-inspired therapeutic delivery

To develop a RBC carrier, a multitude of techniques have been established for
the loading of therapeutic agents without changing RBC’s physiological survival
properties [174]. Of the erythrocyte ghost preparation methods available,
hypotonic treatment is the standard preparation which retains the physiochemical
characteristics of erythrocyte membranes [175, 176]. RBCs are placed in a
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hypotonic solution where osmotic pressure releases the intracellular contents
within the RBC membrane. Meanwhile, the therapeutic agent of interest in the
solution can then passively diffuse into RBCs and retain inside the cells via
LVRWRQLFEXIIHUUHVHDOLQJ'XHWRWKHSLRQHHULQJVWXGLHVXVLQJ5%&VWRGHOLYHUȕJOXFRVLGDVHDQGȕ-galactosidase for the treatment of Gaucher’s disease [177],
several enzyme replacement therapeutics have been developed, some of which
have entered long-term clinical trials [178-181]. Furthermore, erythrocyte ghosts
have been harnessed for the delivery of oligonucleotides [182] and plasmid DNA
[183]. RBC carriers have also been used to entrap small drug molecules [184],
increasing biodistribution of the drug. Likewise, the encapsulation of multiple
drugs have been studied [185]. Erythrocyte ghosts engineered to contain
hemagglutinin fusion protein found on lipid membranes and for encapsulation of
superparamagnetic nanoparticles and anti-cancer drug decitabine has been
made for sustained and targeted delivery [186].
RBC membrane-derived liposomes, termed nano-erythrosomes, were first
reported by Lejeune et al. [187]. Recently, Hu et al. used the plasma membrane
of erythrocyte ghosts to cloak biodegradable polymeric nanoparticles via
membrane extrusion and demonstrated extended blood circulation half-life time
of RBC membrane-camouflaged polymeric nanoparticles [188]. Compared to
PEG-coated nanoparticles, which had an elimination half-life of 15.8 hours, the
RBC-membrane-coated nanoparticles had an elimination half-life of 39.6 hours
nearly double that of the control. Another way in which researchers are taking
advantage of the properties of RBCs is through the coupling of therapeutic agents
onto the outer surface of RBCs by covalent conjugation [189]. Taking advantage
of ligands on the RBC surface, such as the complement receptor 1, drugs can be
conjugated and their circulation time increased. A “hitchhiking” strategy was
employed to attach therapeutic polymeric nanoparticles on the surface of RBCs
through physical means and showed a drastic improvement in blood circulation
time [190].
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1.6.2.

Carrier cells for therapeutic delivery

Natural carrier cells such as cytokine-induced killer (CIK cells), T cells and
mesenchymal stem cells (MSCs) have all been exploited for the delivery of
various therapeutic agents and for the delivery of oncolytic viruses. An advantage
of using these cells is for their tumor-homing or tumor targeting abilities.
Moreover, addition of therapeutic agents into these cells does not affect the
integrity of the natural particulates. CIK cells have demonstrated the ability to
localize into leukemia tissue and become toxic to them [191]. CIK cells have
shown effective in the treatment of several solid malignancies including those of
the lungs and ovaries [192, 193]. Success of CIK treatment in vivo has led to
clinical studies of the treatment for solid tumors with encouraging results [194].
Similar to CIK cells, T-cell based immunotherapies have shown successful
in tumor immunotherapy by increasing the numbers of endogenous NK and CD8+
T cells which are potent mediators of antitumor immunity [195, 196]. Recently, T
cells co-transduced with prostate tumor antigens to target tumor cells were
successfully used for tumor treatment by Kloss et al. [197]. In the study, T cells
were rendered tumor specific and elicited complete tumor remission without
sacrificing T cell reactivity.
MSCs exhibit migratory properties which make them attractive candidates
for targeted delivery of genes and viruses. Recent studies have shown that MSCs
are not only able to migrate to and incorporate within the connective tissue of
tumors, but actively seek out metastases far removed from the primary tumor site
[198-200]. MSCs have been utilized as delivery vehicles of interleukins in order
to improve the anticancer immune surveillance by activating cytotoxic
lymphocytes and NK cells [201]. MSCs have also been used as delivery agents
for gene-directed enzyme prodrug therapy. Several prodrug-enzyme activation
schemes are available for killing tumor cells and are being evaluated in clinical
trials [202]. The approach of using MSCs to deliver a gene to a prodrug was first
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explored by Aboody et al. through delivery of cytosine deaminase (CD) which can
be used for activation of prodrug 5-fluorocytosine to 5-fluorouracil [203]. Kosaka
et al. evaluated the effect of MSC transfection with adenovirus carrying CD
followed by treatment of 5-fluorosytosine in vivo [204]. Their results showed that
delivery of MSCs transfected with CD resulted in significant prolongation of
survival of rats with glioma cells. Fei et al. transfected MSCs with lentiviral vectors
expressing CD with similar success in decreased tumor viability [205]. Other
prodrug-gene combinations have been studied in conjunction with MSCs. Mori et
al. transfected HSV-TK into MSCs then treated glioma cells with the MSCs/TK
followed by treatment with ganciclovir [206]. Their results showed that significant
cell death occurred in glioma cells treated with MSCs/TK compared to nontransfected MSCs. The use of MSCs for GDEPT and as targeting vehicles is
proving very promising for treatment of various cancer types.
1.6.3.

Pathogen-inspired therapeutic delivery

As our understanding of the methods by which pathogens evade the immune
system has grown, the ability to apply the immune evasion capabilities of
pathogens to material design has been developed. One of the earliest attempts
to exploit a naturally derived polysaccharide was through the coating of
liposomes with linear dextran [207]. Bacterial dextran is produced by the
fermentation of sucrose with Leuconostoc mesenteroides [208]. After ethanol
precipitation from the culture medium, acid hydrolysis is used to reduce the
overall molecular weight of dextran. Dextran with an average molecular weight of
70 kD has been used as a plasma volume expander [209]. Dextran coating
enhances the circulation time of drug molecules [210] and stability of micelle
carriers [75]. Coating of poly(lactic acid) nanoparticles with dextran induced a
diminished protein adsorption [211]. Dextran coating prolonged the blood
circulation time of carriers made of poly(methyl methacrylate) polymer [212] and
contrast agents [213]. Hyaluronan covalently attached to the surface of lipid
nanoparticles has been demonstrated to endow the carriers with extended
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circulation and active targeting towards hyaluronan receptor CD44, which is
highly expressed on tumors [214].
Heparin is known to modulate the action of several systems including viral
entry

[215]

and

angiogenesis

[216].

Heparin

is

a

member

of

the

glycosaminoglycan family of carbohydrates and found on the surface of cells and
in the extracellular matrix [217]. It is known that heparin-like polysaccharides can
be obtained from microorganisms such as Escherichia coli and resembles a type
II glycosaminoglycuronan chain [218]. Due to its biological and pharmacological
activities heparin has been used to surface-functionalized a variety of
nanoparticles [219]. Heparin-coated poly(methyl methacrylate) nanoparticles
exhibited a prolonged blood circulation time for 2 days, because host factor H
can bind to heparin and inhibit complement activation [212]. Recently, a heparinmimicking polymer conjugate was synthesized by Nguyen et al. [220]. The
synthesized heparin was far more stable under stress than the control without
sacrificing the native activity of heparin.
1.6.4.

CD47

In 2000, Oldenborg et al. reported that CD47 functioned as a “marker of self” on
murine RBCs [221]. Murine RBCs deficient in CD47 were rapidly cleared from
the bloodstream by macrophages compared to wild-type mice. Indeed, as a RBC
ages, CD47 expression levels decrease (30% lower expression of CD47) on the
oldest RBCs compared to the youngest RBCs, clearly supporting the role of
CD47 in long-term circulation of RBCs in the bloodstream [222]. CD47 is widely
expressed on a majority of normal tissues in humans and other mammals and
leads to the phagocytosis of aged or damaged cells [223]. CD47 regulates
SKDJRF\WRVLV E\ LWV LQWHUDFWLRQ ZLWK VLJQDO UHJXODWRU\ SURWHLQ DOSKD 6,53Į  RQ
macrophages [224]7KURXJK&'OLJDWLRQZLWK6,53ĮW\URVLQHSKRVSKDWDVHLV
activated and myosin accumulation at the phagocytic synapse is repressed,
leading to inhibition of FcȖ DQG complement receptor mediated phagocytosis
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[225].

If the inhibitory signals generated by CD47-6,53Į DVVRFLDWLRQ DUH

sufficient to counteract the phagocytic signals mediated through FcȖ DQG WKH
complement receptors, ingestion of particles (e.g., RBCs or CD47-tagged drug
carriers) is reduced or inhibited (Figure 1.7).
Moghimi et al., suggested that CD47 could represent a viable solution in
the design of macrophage-evading therapeutic carriers [218]. Hsu et al. first
demonstrated the antiphagocytic effect of soluble CD47-streptavidin (CD47-SA:

Figure 1.7. The interaction of phagocyte receptors and an opsonized particle
tagged with CD47 ligand. 7KH LQWHUDFWLRQ RI 6,53Į DQG &' JHQHUDWHV DQ
antiphagocytic signal onto the particle and competes against the phagocytic signal
triggered by FcȖ-IgG binding. If the negative signal dominates in this tug of war,
the particle gets the chance to avoid phagocytic internalization.

containing only the extracellular domain of CD47) fusion protein, expressed in
BL21 bacteria and then purified by biotinylated agarose column, on macrophage
cells [226]. In the study, it was shown that perfluorocarbon-based oxygen carriers
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were able to avoid being engulfed by J774A.1 macrophage cells for up to 2 hours
after cells were pretreated with soluble CD47-SA for 1 hour.
Tsai et al. employed mammalian CHO cells transfected with CD47encoding plasmid (containing only extracellular domain sequence of CD47) to
produce and biotinylate extracellular domain of CD47 ligand [227]. Streptavidincoated polystyrene microbeads of 2.1 μm in diameter were tagged with
biotinylated CD47 with a density comparable to that on RBCs and exhibited
significant phagocytosis resistance with THP-1 macrophages. Recently,
Rodriguez et al. has led to the development of a man-made “Self” peptide which
can inhibit phagocytosis and enhance delivery of nanoparticles [228]. Through
structure biology and computer simulation, a 21-amino acid “Self” peptide
fragment (shortened from the 117-amino acid extracellular domain of CD47). This
peptide was then put onto fluorescent polystyrene nanobeads of size 160 nm.
Within half an hour, the beads tagged with the peptide showed 4 times as many
beads still in circulation compared to the control beads. Additionally, delivery of
paclitaxel to tumor bearing mice with the peptide-tagged polystyrene nanobeads
showed similar tumor size reduction as delivery by the standard paclitaxel carrier
(i.e., Cremophor) without similar toxic side effects.
1.7.

RATIONALE AND HYPOTHESIS

Cancer is a leading cause of death worldwide and was the cause of 8.2 million
deaths in 2012. It is expected that the number of cancer cases will rise from 14
million in 2012 to 22 million within the next two decades [229]. Despite
considerable advances in surgical and adjuvant therapies, many forms of cancer
still show resistance to treatment. One way researchers are combating cancer is
through gene therapy, which is the insertion of genetic material into an
individual’s cell to treat a disease. One approach scientists are using gene
therapy to treat cancer is through GDEPT. In such an approach, a prodrug, a
pharmacologically inactive molecule that requires enzymatic and/or chemical
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transformation to release a cytotoxic drug, is given to the patient. The prodrug
contains the drug which will be used to destroy the targeted cancer cells. The
gene for a foreign enzyme and the prodrug are administered in a two-step
process. That is, first the foreign gene is introduced into the targeted cancer cells,
expressed and released into the cytoplasm and then the prodrug is administered.
The prodrug is activated by the gene-expressed exogenous enzyme and
converted to its cytotoxic form.
My thesis examines the potential of multifunctional polymeric prodrug
micelles for cancer gene therapy. I hypothesize that (i) prodrugs ACV, GCV or
5’DFUR can be used as initiators directly in ring-RSHQLQJ SRO\PHUL]DWLRQ RI İcaprolactone to form a hydrophobic prodrug-WDJJHGSRO\ İ-caprolactone) (PCL),
(ii) the prodrugs released from PCL by acid hydrolysis and/or intracellular
esterase can be converted to their active and toxic forms, via overexpressed
enzyme (either HSV-TK or TP) in cancer cells, (iii) through design and synthesis
of polymeric drug/gene nanocarriers, the releasing profile of the prodrugactivating enzyme system will be optimized to achieve maximum anticancer
effectiveness in both the classical two-step and a proposed one-step approach,
and (iv) CD47-streptavidin bound to the micelle surface can endow
antiphagocytic and targeting properties to the micelle nanocarrier.
1.8.
1.8.1.

SPECIFIC AIMS
Specific aim 1: Optimization of polymeric prodrug nanocarriers

The anticancer prodrugs ACV, GCV and 5’DFUR will be utilized as initiators in
the ring-RSHQLQJSRO\PHUL]DWLRQRIİ-caprolactone to form hydrophobic prodrugtagged PCL, which will be grafted with hydrophilic polymers (methoxy
poly(ethylene glycol), polyethyleneimine, or chitosan) to form amphiphilic
copolymers for the preparation of stable micellar nanoparticles. The synthesized
prodrug-containing amphiphilic copolymers will be characterized accordingly
using analytical tools. Experiments including self-assembly morphology, particle
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size and charge, and critical micelle concentration will be used to determine the
optimal parameters for polymeric nanocarrier formation. I will examine the degree
of the prodrug released from synthesized amphiphilic polymers by using
hydrolysis and esterase. Toxicity of the micelles will be determined against HT29
colorectal cancer cell lines.
1.8.2.

Specific aim 2: Efficacy of polymeric prodrug nanocarriers on cancer
cell treatment

Polymeric micelles with promising features will be employed for both two-step
and one-step toxicity studies. HT29 colorectal cells have been chosen as the
biological model for cytotoxic studies. Because HT29 cells have endogenous TP,
micelles formed with 5’DFUR will be used to encapsulate DOX or SN-38. 5’DFUR
and chemotherapy drugs loaded into my most desirable polymeric nanocarriers
will both be slowly released within the malignant cells possibly extensively
enhancing the effectiveness of anticancer therapy by synergistic or additive
activity. Micelles formed from ACV or GCV will be studied by two-step toxicity by
delivering HSV-TK gene plasmid to cells. The one-step approach will be achieved
by synthesizing polymeric nanocarriers containing prodrug and gene encoded
plasmids and culturing with cancer cells. To achieve maximal anticancer
effectiveness of my one-step approach using multifunctional polymeric
nanocarriers, the releasing profile of prodrug-activating enzyme will be modulated
in line with the prodrug releasing window.
1.8.3.

Specific aim 3: Antiphagocytic and targeted micelle carriers

CD47-streptavidin fusion protein can be easily attached to biotyinylated
substrates utilizing the biotin-streptavidin affinity, revealing antiphagocytic
function. Furthermore, since CD47 is an integrin associated protein, it has the
potential to be employed to target integrin Įvȕ3, which is overexpressed on tumoractivated neovascular endothelial cells and unexpressed on mature quiescent
30

ones lined in blood vessels. Because the affinity of biotin to streptavidin is so high
and the micelle surface does not have other proteins, the crude protein can be
used for CD47 functionalization on the micelle surface. Here, micelles will be
biotinylated and then bound with CD47-streptavidin crude protein. The CD47
coated micelle will then be treated to macrophages and the antiphagocytic effect
studied. Moreover, PC3 cells, which over express Įvȕ3 integrin, will be treated
with CD47 tagged micelles and the targeting ability followed.
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CHAPTER 2:

POLYMERIC

MICELLES

FOR

ACYCLOVIR

DRUG DELIVERY2
2.1.

ABSTRACT

Polymeric prodrug micelles for delivery of acyclovir (ACV) were synthesized.
First, ACV was used directly to initiate ring-RSHQLQJ SRO\PHUL]DWLRQ RI İcaprolactone to form ACV-polycaprolactone (ACV-PCL). Through conjugation of
hydrophobic ACV-PCL with hydrophilic methoxy poly(ethylene glycol) (MPEG) or
chitosan, polymeric micelles for drug delivery were formed. 1H NMR, FTIR, and
gel permeation chromatography were employed to show successful conjugation
of MPEG or chitosan to hydrophobic ACV-PCL. Through dynamic light scattering,
zeta potential analysis, transmission electron microscopy, and critical micelle
concentration (CMC), the synthesized ACV-tagged polymeric micelles were
characterized. It was found that the average size of the polymeric micelles was
under 200 nm and the CMCs of ACV-PCL-MPEG and ACV-PCL-chitosan were
2.0 mg L-1 and 6.6 mg L-1, respectively. The drug release kinetics of ACV was
investigated and cytotoxicity assay demonstrates that ACV-tagged polymeric
micelles were non-toxic.
2.2.

INTRODUCTION

Due to the fact that nanoparticles can be prepared using a variety of polymers,
biodegradable polymers have been extensively studied for the field of polymer
therapeutics [1-3]. While there have been many biodegradable polymeric
nanoparticles synthesized for drug delivery, polymeric micelles have numerous
advantages over other proposed colloidal delivery systems [4-7]. Many studies
have shown the promise micelles have for drug delivery because they can be
tailored for prolonged blood circulation time, cellular selectivity, and for their
2

The material contained in this chapter was previously published in Macromolecular
Research 20, (2012) 1-4, and Colloids and Surfaces B: Biointerfaces 122 (2014) 73845.
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controlled release capabilities [8-10]. In addition, micelles can be specifically
synthesized to increase a drug’s solubility and bioavailability [11-14].
Acyclovir (ACV) is a guanosine-based prodrug most commonly used for
the treatment of infections caused by herpes simplex virus (HSV) type 1 and 2,
varicella zoster virus and, to a lesser extent, cytomegalovirus and Epstein-Barr
virus [15]. Moreover, prodrug ACV can be converted to its cytotoxic
phosphorylated form by herpes simplex virus thymidine kinase (HSV-TK) gene
for cancer therapy [16]. That is, if the HSV-TK gene is delivered to actively
dividing cancer cells, and ACV is subsequently administered to the cells, the TK
enzyme phosphorylates ACV, yielding toxic metabolites which cause death in
prodrug treated HSV-TK expressing cells [17-19]. However, due to ACV’s poor
water solubility and ensuing low bioavailability, alternative delivery approaches
are required to increase the therapeutic potential of ACV. Several methods
reported are to couple ACV to biocompatible hydrophilic polymers [20-22] or
encapsulation into drug carriers [23-25]. Although these processes increase the
bioavailability of ACV as well as offer a practical treatment for patients, they are
labor-intensive and cost-ineffective. As a first step towards the formation of ACVtagged polymeric micelles, we developed a novel technique for direct synthesis
of ACV-PCL through the ring-opening polymeUL]DWLRQRIİ-FDSURODFWRQH İ-CL).
Polymeric micelles consist of an inner core made of a hydrophobic block
copolymer and an outer corona made of the hydrophilic block of the copolymer.
PCL, having been widely used as the core-forming hydrophobic segment of
nanoparticles, was selected as the model polymer for this study. PCL is a semicrystalline, linear resorbable aliphatic polyester. It has been commonly used in
drug delivery systems because it is biodegradable and biocompatible. [26-28]
PCL is commonly synthesized by ring-RSHQLQJSRO\PHUL]DWLRQRIİ-CL using an
alcohol as an initiator and stannous (II) octoate (Sn(Oct)2) as a catalyst [29, 30].
In addition to using alcohol as the initiator, methoxy-poly(ethylene oxide) and
starch have been employed as macroinitiators to form amphiphilic polymers. [31,
47

32]. In this study, prodrug ACV possessing hydroxyl groups was used as the
initiator to obtain prodrug-PCL. Then, a hydrophilic compound (MPEG or
chitosan) was grafted on the hydrophobic prodrug-PCL to form the amphiphilic
block copolymer which already has the drug attached started from the ringopening polymerization. These synthesized ACV-tagged amphiphilic polymers
can self-assemble in aqueous medium to form polymeric prodrug micelles for use
as nanocarriers in drug delivery.
Individual conjugation of ACV-PCL to a wide array of biocompatible
hydrophilic polymers to form polymeric micelles each has their own advantages
for drug delivery. With this in mind, we choose to assess the successful
conjugation of two model hydrophilic polymers, MPEG and chitosan, to
hydrophobic ACV-PCL. Chitosan is a natural polysaccharide derived from
deacetylation of chitin. Chitosan’s biocompatible and biodegradable features
have attracted much attention in biomedical and pharmaceutical research [27,
33]. Similarly, MPEG is a biocompatible hydrophilic polymer commonly used in
polymeric micelle formation. MPEG is inexpensive, non-toxic and is widely used
to covalently modify biological macromolecules and surfaces [10, 34, 35]. Hence,
ACV-PCL-MPEG and ACV-PCL-chitosan copolymers were synthesized. The
chemical structure and physical properties of the copolymers were characterized
and micelle formation investigated. The drug release profiles of ACV from
polymeric prodrug micelles and the biocompatibility of polymeric prodrug micelles
were investigated in this study.
2.3.

MATERIALS AND METHODS

2.3.1.

Materials

ACV was purchased from TCI (Tokyo, Japan). N,N’-dicyclohexyl carbodiimide
'&&  İ-CL, pyrene, and succinic anhydride were purchased from Acros
Organics (Geel, Belgium). Sn(Oct)2, CDCl3 with 1% tetramethylsilane (TMS),
deuterated

dimethyl

sulfoxide

(DMSO-d6),

dimethyl

sulfoxide

(DMSO),

tetrahydrofuran (THF), dichloromethane (DCM), methanol, 2-propanol, hexane,
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toluene, methoxypolyethylene glycol amine (MPEG-NH2; MW = 5,000), and
chitosan oligosaccharide lactate (MW = 5,000) were all purchased from SigmaAldrich (St. Louis, MO). Ethyl ether was purchased from J.T. Baker (Austin, TX).
N-Hydroxysuccinimide (NHS) was purchased from Alfa Aesar (Ward Hill, MA).
Acetone was purchased from Pharmco-AAPER (Shelbyville, KY). Pyridine and
hydrochloric acid (HCl) were purchased from EMD (Philadelphia, PA). Sodium
chloride (NaCl) and magnesium sulfate were purchased from Showa (Tokyo,
Japan). All reagents were used as received without further purification.
2.3.2.

Characterization methods

Gel permeation chromatography (GPC) analyses were performed on a Waters
1525 binary HPLC pump equipped with a Waters 2414 refractive index detector
(Milford, MA). Waters styragel HR 3 (MW = 500 – 30,000) and HR 4E (MW = 50
– 100,000) columns were equipped. Molecular weight calibration was performed
with polystyrene standards that covered a MW range of 400 – 4.3 × 104. GPC
analyses were performed in THF at a flow rate of 1 mL min-1 with an injected
volume of 50 μl. 1H NMR spectra were obtained from a Varian Unity/Inova 400
MHz instrument (Sparta, NJ). To obtain FTIR spectra by a Jasco FTIR-4200
spectrometer (Tokyo, Japan), a small amount of polymeric sample was loaded
onto a silicon wafer and THF was added dropwise to dissolve the sample and
evaporated afterwards. This was repeated until the entire sample was dissolved
and a film had formed.
2.3.3.

Synthesis of ACV-tagged amphiphilic polymers

$&9  PJ  ZDV ZHLJKHG DQG PL[HG ZLWKİ-CL (2.25 mL) under a sonication
bath for 5 min at room temperature. Sn(Oct)2 ZWRIİ-CL) was then added
into the mixture. The entire solution was placed into a 3-necked round-bottom
flask. The system was purged with nitrogen and immersed in an oil bath at 140oC
for 24 h. The crude product was cooled to room temperature, dissolved in DCM,
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and precipitated by cold methanol. The product was then vacuum dried by a
rotary evaporator at 40oC.
ACV-PCL (0.5 mmol) and succinic anhydride (1 mmol) were weighed and
dissolved in toluene in a 3-necked round-bottom flask. One mmol pyridine was
added and the solution was reacted under nitrogen at 70oC for 48 h. The product
was then precipitated by cold hexane, and spun down. The pellet was redissolved in DCM and washed twice each with 10% (v/v) HCl and saturated NaCl
solution. The organic phase was isolated and dried with magnesium sulfate then
filtered. The carboxylated ACV-PCL was recovered by precipitation in cold
hexane and then vacuum dried by rotary evaporation at 40oC.
ACV-PCL-COOH (0.54 mmol) and NHS (2.7 mmol) were weighed and
mixed in 15 mL DCM, and then DCC (2.7 mmol) was added. The reaction was
run under a nitrogen environment at room temperature for 24 h. The precipitated
byproduct 1,3-dicyclohexylurea was removed by vacuum filtration. The filtrate
was added into 35 mL diethyl ether and cooled to 4oC for 4 h to precipitate ACVPCL-NHS. The precipitate was collected by centrifugation at 3,500 rpm for 5 min,
washed with 2-propanol and solvent removed by rotary evaporation at 40oC.
ACV-PCL-NHS (10 mg) and MPEG-NH2 (10 mg) were weighed and
dissolved by 20 mL DCM in a round-bottom flask. The flask was purged with
nitrogen and the solution was stirred for 24 h. The solution was then dialyzed
(MWCO = 6-8 kD, Spectra/Por, Rancho Dominguez, CA) against pure DCM to
remove remaining MPEG-NH2. ACV-PCL-MPEG was recovered by rotary
evaporation at 40oC.
ACV-PCL-NHS (10 mg) was dissolved in 5 mL acetone and slowly added
to chitosan solution (20 mg chitosan oligosaccharide lactate dissolved in 25 mL
deionized water). The mixture, purged with nitrogen, was stirred in a roundbottom flask for 24 h. The reacted solution was vacuum dried to remove acetone
and then lyophilized. The amphiphilic polymer was then dissolved in DCM and
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dialyzed (MWCO = 6-8 kD, Spectra/Por) against pure DCM to remove unreacted
chitosan. ACV-PCL-chitosan was recovered by rotary evaporation at 40oC.
2.3.4.

Preparation of polymeric prodrug micelles

ACV-PCL-MPEG and ACV-PCL-chitosan micelles were formed similarly. Briefly,
10 mg of ACV-tagged amphiphilic polymer was dissolved in 2 mL acetone. The
solution was then added dropwise to 10 mL deionized water under sonication.
Acetone was removed by rotary evaporation and the final solution was collected
by filtering through a 0.45 μm filter.
2.3.5.

Determination of critical micelle concentration

The CMC was estimated by using pyrene as a fluorescent probe [36]. Briefly, 1
mg mL-1 of polymeric prodrug micelle was formed. Various amounts of deionized
water and micellar solution were added respectively to glass vials to obtain
micellar concentrations ranging from 5 × 10-7 to 1 mg mL-1. Pyrene in acetone
was then added separately to the prepared vials to get a final concentration of
pyrene in water of 6.0 × 10-7 mg mL-1, slightly lower than the saturation solubility
of pyrene in water [37]. The solutions were then allowed to equilibrate for 8 h.
Fluorescent spectra were determined by a plate reader (Synergy MX, BioTek,
Winooski, VT) with an excitation wavelength of 334 nm.
2.3.6.

Size and morphology of polymeric prodrug micelles

The average particle size of polymeric prodrug micelles was determined by a
dynamic light scattering (DLS) instrument (Zetasizer Nano ZS, Malvern
Instruments, United Kingdom) equipped with a red laser at a wavelength of 633
nm and scattering angle of 90o at 25oC. The zeta potential of the micelles
dispersed in deionized water was determined with a zeta potential analyzer
(Zetasizer Nano ZS). Transmission electron microscopy (TEM) image of micelles
was performed on a JEM-4000FX (JEOL, Tokyo, Japan) at 80 kV. The TEM
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samples were prepared by adding 10 μL of micellar solution (1 mg mL-1) onto a
Formvar grid for 5 min and wicking away solution in excess. The samples were
negatively stained with 10 μL phosphotungstic acid solution (2 wt%) for 10 sec
and then 15 sec, wicking away excess staining solution each time.
2.3.7.

Drug release kinetics

Polymeric prodrug micelles at a concentration of 1 mg mL-1 were made in
phosphate buffered saline (PBS) (1 M, pH 7.4) at 25oC. Two mL of solution was
placed in a dialysis tube (Float-A-Lyzer, Spectra/Por) with a MWCO of 3.5 – 5
kD. The dialysis bag was then immersed in 50 mL PBS at room temperature. At
specified time intervals, 5 μL of sample was removed and replaced with fresh
PBS. The amount of ACV released was analyzed by a plate reader (BioTek) at
254 nm. All experiments were carried out in triplicate.
2.3.8.

Cytotoxicity test

24-well plates were seeded with human colorectal HT29 cells (HTB-38; ATCC,
Manassas, VA) suspended in 0.5 mL Dulbecco’s modified Eagles’ medium
(DMEM, Corning Cellgro, Manassas, VA) supplemented with 10% fetal bovine
serum (FBS, Atlanta biologicals, Flowery Branch, GA) and 1% penicillinstreptomycin (Sigma) and incubated at 37oC in 5% CO2 balanced with humidified
air for 24 h. In each well, 500 μL of 1 mg mL-1 ACV-PCL-MPEG or ACV-PCLchitosan polymeric micelles (filtered by a 0.22 μm filter) was added. After
incubation for 48 h, cell viability was assessed using MTT assay. 200 μL of sterile
MTT solution (4 mg mL-1) was added into the culture wells and incubated for 4 h.
The medium containing unreacted MTT was removed and 300 μL DMSO was
added to dissolve the insoluble purple formazan crystals formed in cellular
mitochondria. The absorbance at 590 nm was measured with a plate reader
(BioTek) and results were recorded as viability percentage calculated against the
control group without micellar challenge. All experiments were carried out in
triplicate.
52

2.4.
2.4.1.

RESULTS AND DISCUSSION
Synthesis and characterization of amphiphilic prodrug polymers

Figure 2.1. Synthetic scheme of (A) ACV-PCL, (B) ACV-PCL-COOH, (C) ACV-PCLNHS, (D) ACV-PCL-MPEG, and (E) ACV-PCL-chitosan.

ACV-PCL was synthesized through ring-RSHQLQJSRO\PHUL]DWLRQRIİ-CL, which
was initiated exclusively by ACV (Figure 2.1 A). The 1H NMR spectra of
guanosine-based prodrug ACV and ACV-PCL 24 h post-synthesis are shown in
Figure 2.2 (i) and (ii), respectively. Judging from the ACV-PCL spectrum,
chemical shifts at 3.75 (e, f-CH2), 5.44 (d-CH2), 7.68 (b-CH) were assigned to
SURWRQVLQ$&9ZKLOHWKHSHDNVDWį  -CH2), 1.64 (2-CH2), 2.29 (1-CH2)
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and 4.04 (4-CH2) correspond with the backbone chain of PCL polymer. The
characteristic resonances of PCL and ACV were both observed in the
synthesized polymer. Although the characteristic peaks of ACV in Figure 2.2 (ii)
are much lower than those representing PCL, the evidence of coupling of ACV’s
protons in synthesized ACV-PCL is clear.

Figure 2.2. 1H NMR spectra of (i) ACV and (ii) ACV-PCL.

By 1H NMR spectra, the number average degree of polymerization was
determined by taking the ratio of the integral values of the resonance peaks
corresponding to the terminal methylene proton signal of PCL to the internal
methylene proton signal of PCL according to the following equation:

Degree of Polymerization (Xn, NMR) =

I 4  I 4'
I 4'

(1)

Where I 4 and I 4 , are the peak areas for the internal methylene protons of PCL
'

(4.04 ppm) and the terminal methylene protons of PCL (3.63 ppm), respectively.
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Table 2.1. Number-averaged molecular weight (Mn) and degree of polymerization (Xn)
of ACV-PCL prepared by the ring-opening polymerization of İ-CL using ACV as the
initiator and Sn(Oct)2 as the catalyst
Time
(min)

Mna
(Da)

Xn GPCa

Xn NMRb

1440

8812

75.2

55.3

120

8356

71.2

50.3

60

8020

68.3

44.0

40

5819

49.0

42.7

30

5834

49.1

24.6

20

1388

10.2

19.8

a

Calculated by GPC, bCalculated by 1H NMR

Table 2.1 summarizes the results concerning the ring-opening
polymerization of ACV-PCL. It clearly indicates that polymers with high molecular
weight were obtained given sufficient reaction time. The number-average
molecular weight (Mn) obtained via GPC increases as the polymerization reaches
completion. By 60 min, the polymerization was unimodal and there was little
change in molecular weight (Mw) and Mn shows that the reaction is nearing
completion. Degree of polymerization (Xn,GPC) was obtained by GPC according to
the following equation:

X n, GPC

(M n  M ACV )
MH - CL

(2)

There is some discrepancy between the Xn obtained from GPC and NMR data.
This is because GPC data was calibrated relative to polystyrene standards. It is
surmised that the deviation could be decreased if attempts are made to correct
the GPC data by using the Mark-Houwink equation [30, 38].
ACV-PCL was further conjugated with either MPEG or chitosan as shown
in Figure 2.1 B-E. Successful conjugation of MPEG or chitosan was confirmed by
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GPC, 1H NMR and FTIR analyses. The increase in Mn of ACV-PCL to 22 kDa
from 17.5 kDa corresponds with the addition of MPEG (Table 2.2). Figure 2.3
shows the 1H NMR of MPEG-NH2 and ACV-PCL-MPEG. The peak at 3.63 (AOCH2) attributed to MPEG can be clearly seen in Figure 2.3 (iv). Due to the
conjugation of MPEG to ACV-PCL though amide linkage (Scheme 2.1 D), the
change of the peak at 1.79 (B-NH2) from a singlet in Figure 2.3 (iii) to a multiplet
in Figure 2.3 (iv) further confirms conjugation of MPEG to ACV-PCL. Further
characterization of successful grafting of MPEG to hydrophobic ACV-PCL was
examined through FTIR analysis. FTIR spectra of ACV-PCL (A), MPEG-NH2 (B)
and ACV-PCL-MPEG (C) are shown in Figure 2.4. C-H stretching vibrations can
be seen from 2945-2852 cm-1 for all samples. The typical bending vibration of
1634 cm-1 for the NH2 bending amide I band can be seen in ACV-PCL and ACVPCL-MPEG spectra, and is attributed to ACV. PCL and MPEG blocks were
characterized by prominent absorptions at 1726 cm-1 (C=O) and 1112 cm-1 (CO-C), respectively. These peaks are found in ACV-PCL-MPEG copolymer
ascertaining successful bonding of MPEG to ACV-PCL.
Table 2.2. Characterization of ACV-PCL grafted with hydrophilic polymersa

a

Sample

Mw
(Da)

Mn
(Da)

Polydispersity
(Mw/Mn)

ACV-PCL (24 h)

28640

17491

1.64

ACV-PCL-MPEG

31746

22399

1.41

ACV-PCL-chitosan

30916

21745

1.42

Measured by GPC

GPC analysis revealed that the Mn of ACV-PCL increased from 17.5 kDa
to 21.7 kDa after grafting with chitosan and had a PDI of 1.42 (Table 2.2).
Successful conjugation of chitosan to ACV-PCL was characterized similar to
ACV-PCL-MPEG. Figure 2.5 reveals the 1H NMR of chitosan (v) and ACV-PCLchitosan (vi). As shown in Scheme 2.1 E, conjugation of chitosan to ACV-PCL is
made via amide linkage. The peak at 1.79 (A-NH2) from a singlet to a multiplet in
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Figure 2.5 (vi) confirms conjugation of chitosan to ACV-PCL. Moreover, the peaks
from the aromatic protons on C3 – C6 FDQEHVHHQIURPį – 3.85, slightly
shifted downward from the peaks shown in the original chitosan sample.

Figure 2.3. 1H NMR spectra of (iii) MPEG and (iv) ACV-PCL-MPEG.
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Figure 2.4. FTIR spectra of (A) ACV-PCL, (B) MPEG-NH2, and (C) ACV-PCL-MPEG.

Figure 2.5. 1H NMR spectra of (v) chitosan and (vi) ACV-PCL-chitosan.
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Figure 2.6 depicts the FTIR spectra of ACV-PCL (A), chitosan (B), and
ACV-PCL-chitosan (C). OH stretching from 3429 – 3167 cm-1 as well as peaks at
1634 cm-1 and 1521 cm-1 corresponding to the N-H bending vibrations of the
amide I and II bands are attributed to ACV and chitosan, respectively. The
aforementioned peaks as well as the carbonyl absorption at 1726 cm-1 associated
with PCL and a peak at 1065 cm-1 (C-O-C) seen in each spectra are found in
ACV-PCL-chitosan. The FTIR results are in line with the results from 1H NMR
and demonstrate successful synthesis of ACV-PCL-chitosan.

Figure 2.6. FTIR spectra of (A) ACV-PCL, (B) chitosan, and (C) ACV-PCL-chitosan.

2.4.2.

Formation and characterization of ACV-tagged polymeric micelles

Due to the amphiphilic nature of the synthesized ACV-PCL copolymers (i.e.,
ACV-PCL-MPEG and ACV-PCL-chitosan), they can self-assemble into polymeric
prodrug micelles in aqueous medium. Here, ACV-PCL acts as the hydrophobic
segment and MPEG or chitosan serve as the hydrophilic segments. Polymeric
micelles of ACV-PCL copolymer were prepared via the evaporation method [39].
The CMC using pyrene as a hydrophobic fluorescent probe was carried out to
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prove the formation of the micellar structures. Pyrene can preferentially partition
into the interior hydrophobic microdomains and change the intensities of the first
and third bands in the pyrene fluorescence spectrum [37] For ACV-PCL-MPEG
the shift found in the first and third bands was at I335/I330 while for ACV-PCLchitosan it was at I337/I332. It is believed that this change is due to different polymer
compositions. Figure 2.7 A shows the CMC values of ACV-tagged polymeric
micelles in aqueous medium. It was determined that the CMCs for ACV-PCLMPEG and ACV-PCL-chitosan were 2.0 and 6.6 mg L-1, respectively (Figure 2.7
A (i) and (ii)). Kim et al. reported that the CMC values of block copolymers
depends upon the block copolymer architecture [40]. In this study, the
hydrophobic block was kept constant, as ACV-PCL, while the hydrophilic block
was changed to either MPEG or chitosan. The low CMC value obtained for ACVtagged polymeric micelles could provide evidence for their stability in dilute
solutions.
In order to characterize the morphology of ACV-tagged polymeric micelles,
DLS and TEM analyses were carried out. Figure 2.7 B shows the size and
morphology of ACV-tagged polymeric micelles. As can be seen from DLS results,
sizes of the two types of polymeric prodrug micelles were under 200 nm. ACVPCL-MPEG (Figure 2.7 B (i)) and ACV-PCL-chitosan (Figure 2.7 B (ii)) micelles
showed size distributions with mean diameters of 142.8 and 172.7 nm,
respectively. The morphology of the micelles was further examined by TEM as
shown in the insets of Figure 2.7 B. The size of the micelles in the TEM images
was slightly lower than the results from DLS with an average particle size of ~100150 nm. This size fluctuation is due to the fact that DLS records the hydrodynamic
radius of particles which is often times slightly larger than the actual particle size.
Zeta potential analysis of ACV-tagged polymeric micelles was also performed.
An average zeta potential for ACV-PCL-MPEG micelles was 1.4 mV. Due to the
fact that MPEG has a neutral charge, the results obtained for ACV-PCL-MPEG
micelles are reasonable. In contrast, the detected zeta potential of ACV-PCL60

chitosan micelles was 32.3 mV. This is attributed to the positive charge of the
hydrophilic chitosan segment deployed on micellar nanoparticles.
To determine the drug loading percentage of ACV per mg of micelle
formulation, the absorbance of ACV-tagged polymeric micelles at t = 0 and t = 48
h was examined and compared to a standard calibration curve of ACV ranging
from 0.002 to 1.0 mg/mL. It was found that ACV comprised 8.7% and 3.2% of
ACV-PCL-MPEG and ACV-PCL-chitosan micelles, respectively. The difference
in ACV loading percentage is due to different conditions employed for the
synthesis of ACV-PCL-MPEG and ACV-PCL-chitosan amphiphilic copolymers.
While MPEG-NH2 can dissolve in organic solvent, chitosan requires an aqueous
solvent for it to dissolve. Therefore, for ACV-PCL-chitosan synthesis, the ester
bond between ACV and PCL is already weakened, thereby resulting in less ACV

Figure 2.7. (A) Plot of the intensity ratio (II/IIII) versus concentration of ACV-tagged
polymeric micelles, and (B) particle size distribution of (i) ACV-PCL-MPEG and (ii)
ACV-PCL-chitosan. Insets represent TEM images.
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coupled with PCL than ACV-PCL-MPEG which is synthesized under organic
solvent environment.
2.4.3.

In vitro release of ACV from polymeric micelles

The in vitro release behaviors of ACV from both types of polymeric prodrug
micelles in PBS at 25oC were studied and the results are shown in Figure 2.8 and
2.9. A Similar biphasic drug release profile of ACV-PCL-MPEG and ACV-PCLchitosan micelles was observed, with initial burst release within the first 2 h (~
50% accumulative release) followed by a sustained release pattern up to 48 h.
The release of ACV from both polymeric prodrug micelles was caused by the
hydrolysis of ester linkage between ACV and PCL. In the first phase, the rate of
drug release from ACV-PCL MPEG micelles was relatively rapid than that from
ACV-PCL-chitosan ones. The reason for this phenomenon is speculated to be
twofold. First, MPEG chains probably are more hydrophilic and flexible than
chitosan chains on micellar nanoparticles, leading to a faster hydrolysis and
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Figure 2.8. In vitro drug release profile of ACV-PCL-MPEG in PBS (mean ± SD, n =
3).
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concomitant ACV diffusion from hydrophobic PCL cores. Second, the diffusion of
ACV molecules might be slowed down by the positively charged chitosan on
ACV-PCL-chitosan micelles. Such different initial release trend continued and
resulted in higher ACV accumulative release from ACV-PCL-MPEG micelles
(96%) than from ACV-PCL-chitosan micelles (82%).
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Figure 2.9. In vitro drug release profile of ACV-PCL-chitosan in PBS (mean ± SD, n
= 3).

The release of ACV from the prodrug tagged micelles was modeled using
both Langmuir and Power Law models. It can be seen from Figure 2.8 and 2.9,
that the Power Law was not a good fit for release of ACV from polymeric micelles.
Here, n was equal to 0.19 and 0.21 in ACV-PCL-MPEG and ACV-PCL-chitosan,
respectively. The exponent, n, of a sphere with Fickian diffusion as the drug
release mechanism is 0.43 [41], because our exponents are lower than this value,
the drug release mechanism of ACV from polymeric micelles is not solely through
diffusion. This makes sense seeing as we believe that the ester bond between
prodrug ACV and PCL is broken via hydrolysis. Therefore, first the bond must be
broken and then ACV can diffuse out of the micelle carrier. In contrast to the
63

Power Law, the Langmuir model fit the release of ACV from polymeric micelles
well. The Langmuir model, is an enzyme kinetics model, and because ACV is
released via reaction diffusion, the dissolution is taken into account with this
model. Here, we found that the dissociation constant (Kd) was equal to 1.40 and
1.14 in ACV-PCL-MPEG and ACV-PCL-chitosan, respectively.
2.4.4.

Cytotoxicity study

Biocompatibility is a vital necessity of polymer materials being used for drug
delivery applications. To evaluate if ACV-tagged polymeric micelles showed any
cytotoxicity towards HT29 colorectal cells, MTT assay was performed. As shown
in Figure 2.10, the viability of HT29 cells after treatment for 48 h with either ACVPCL-MPEG or ACV-PCL-chitosan has little change compared with the untreated
control cells (i.e., cells without any micelle challenge). These results demonstrate
that ACV-tagged polymeric micelles do not exhibit apparent toxicity, and are
biocompatible.

Figure 2.10. Viability of HT29 colorectal cancer cells challenged with ACV-tagged
polymeric micelles at different dosages.
Control (without micelle challenge),
ACV-PCL-MPEG micelles, and
ACV-PCL-chitosan micelles (mean ± SD, n = 3).
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2.5.

CONCLUSION

In this study, ACV-PCL-MPEG and ACV-PCL-chitosan polymeric micelles were
synthesized and characterized. ACV was used to directly initiate polymerization
RI İ-CL to form hydrophobic ACV-PCL. Compared to conventional methods of
incorporating ACV into polymeric carriers by chemical conjugation or physical
encapsulation, our approach is advantageous in terms of eliminating drug-loading
steps, enhancing drug-carrying capacity, and decreasing production cost. By
grafting ACV-PCL with either MPEG or chitosan, ACV-tagged amphiphilic
polymers can self-assemble as micellar nanoparticles in aqueous medium.
Structural analyses such as 1H NMR and FTIR were performed to confirm their
conjugation. ACV-tagged polymeric micelles were found to have a mean size
under 200 nm by both DLS and TEM and have a low CMC. Moreover, both ACVPCL-MPEG and ACV-PCL-chitosan micelles were non-toxic to HT29 colorectal
cells. ACV-tagged polymeric micelles are potential carriers for therapeutic and
anticancer drug delivery.
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CHAPTER 3:

GANCICLOVIR

INTEGRATED

POLYMERIC

NANOCARRIERS FOR GENE-DIRECTED ENZYME PRODRUG
THERAPY3
3.1.

ABSTRACT

The most prominent suicide gene therapy is the use of herpes simplex virus
thymidine kinase (HSV-TK) in conjunction with guanosine-based prodrug
ganciclovir (GCV). This is a two-step process whereby first the gene (HSV-TK) is
delivered to targeted cells and then the prodrug (GCV) is administered where it
is then activated to its cytotoxic form, GCV-TP by the gene-expressed exogenous
enzyme. Here, we propose a one-step delivery of gene and prodrug through
polymeric micellar nanocarriers. In this study, Guanosine-based GCV was used
as the initiator in ring-opening polymerization of İ-caprolactone to form
hydrophobic GCV-PCL which was then grafted to hydrophilic chitosan to form
amphiphilic copolymers for the preparation of stable micellar nanoparticles.
Successful synthesis of amphiphilic copolymers was followed by 1H NMR and
FTIR. Self-assembly behavior of micellar nanoparticles was determined by TEM,
particle size and charge and critical micelle concentration (CMC). Polymeric
nanocarriers with optimal characteristics encoded with HSV-TK plasmids were
cultured with parental HT-29 colorectal cancer cells and toxicity measured. 1H
NMR analysis shows successful synthesis of GCV-PCL. FTIR spectra reveal
characteristic absorption peaks associated with chitosan and PCL are
simultaneously present in amphiphilic copolymer GCV-PCL-chitosan. CMC of
GCV-PCL-chitosan copolymer was measured to be 11.2 mg L-1 while size
measured by dynamic light scattering was detected to be 93.4 nm, with a zeta
potential of +38.5 mV. Toxicity results demonstrate that GCV-PCL-chitosan/TK
nanovectors are a feasible approach to kill HT29 colon cancer cells.
3.2.

INTRODUCTION

3

The material contained in this chapter is planned for publication in Molecules and
Macromolecular Bioscience.
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Gene-directed enzyme prodrug therapy (GDEPT) is one of the most important
and successful prodrug delivery approaches for cancer therapy. In GDEPT, a
prodrug, a pharmacologically inactive molecule that requires enzymatic and/or
chemical transformation to release a cytotoxic drug, is given to the patient. The
prodrug contains the drug which will be used to destroy the targeted cancer cells.
The gene for a foreign enzyme and the prodrug are administered in a two-step
process. That is, first the foreign gene is introduced into the targeted cancer cells,
expressed and released into the cytoplasm and then the prodrug is administered.
The prodrug is activated by the gene-expressed exogenous enzyme and
converted to its cytotoxic form [1, 2].
The most prominent GDEPT pair is the use of herpes simplex virus
thymidine kinase (HSV-TK) in conjunction with a variety of guanosine-based
prodrugs [3-5]. Ganciclovir (GCV) is the most widely used prodrug for HSV-TK,
and is a well-known antiviral agent [3, 6-8]. The HSV-TK/GCV system has been
used in the treatment of brain tumors [9, 10], colorectal tumors [11-13], and oral
cancer [14]. Research has shown that HSV-TK/GCV exhibits not only direct
cytotoxicity but also a bystander effect, which builds up the efficiency of the HSVTK/GCV system in destroying malignant cells [13, 15, 16]. However, significant
therapeutic benefit has yet to be demonstrated; most likely limited by inefficient
gene and drug delivery to tumor cells. Most GDEPT studies, and those which
have reached clinical trials, have been focused on using viral vectors to deliver
the prodrug and activating gene [17, 18]. However, viruses harnessed in the gene
therapy field are notorious for causing immunogenicity and tumorigenicity [19].
Safety concerns associated with viral vectors have prompted researchers to
develop non-viral vectors for gene delivery.
In particular, polymeric nanoparticles have attracted attention because of
their potential applications in medicine and pharmacy as drug delivery carriers.
In recent years, polymeric micelles have been the focus of much interest as
alternative vehicles for the solubilization of poorly water-soluble molecules
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rendering clear advantages over current solubilizing agents in drug delivery [20].
Polymeric micelles are expected to withstand the diluting effect of blood, stay in
a micellar form and even act as a circulating depot drug delivery system after
intravenous administration. Moreover, there is no inclusion of potentially harmful
surfactants and excipients in the process of encapsulating hydrophobic drug
molecules. Due to the fact that micelles can be specifically synthesized to
increase a drug’s solubility and bioavailability, they are a model system for
GDEPT [21-24].
3RO\ İ-caprolactone) (PCL) having been widely used as the core-forming
hydrophobic segment of nanoparticles was selected as the model polymer for
this study. PCL is a semi-crystalline linear resorbable aliphatic polyester. It has
been commonly used in drug delivery systems because it is biodegradable and
biocompatible [25-27]. PCL is commonly synthesized by ring-opening
SRO\PHUL]DWLRQ RI İ-caprolactone using an alcohol (R-OH) as an initiator and
stannous (II) octoate (Sn(Oct)2) as a catalyst [28, 29]. In addition to using R-OH
as the initiator, methoxy-poly(ethylene oxide) and starch have been employed as
macroinitiators to form amphiphilic polymers [30, 31]. In this study, prodrug GCV
possessing hydroxyl groups was used as the initiator to obtain GCV-PCL. Then,
hydrophilic chitosan was grafted on the hydrophobic GCV-PCL to form the
amphiphilic block copolymer which already has the drug attached started from
the ring-opening polymerization. Chitosan is a natural polysaccharide derived
from deacetylation of chitin. Chitosan’s biocompatible and biodegradable
features attract much attention in biomedical and pharmaceutical research [25,
31].
The synthesized GCV-tagged amphiphilic copolymer can be selfassembled in aqueous medium to form polymeric prodrug micelles and were
used to evaluate anticancer effectiveness to HT29/TK cells (cells which
overexpressed HSV-TK gene plasmid). Moreover, the positive charge endowed
on the micelles by chitosan was used to bind HSV-TK gene plasmid onto the
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micelles for a one-step GDEPT cancer therapy to parental HT29 colorectal cells.
Our results indicate that GCV-PCL-chitosan/TK micelles are effective carriers for
GDEPT.
3.3.

MATERIALS AND METHODS

3.3.1.

Materials

GCV was purchased from TCI (Tokyo, Japan). N,N’-dicyclohexyl carbodiimide
'&&  İ-CL, pyrene, and succinic anhydride were purchased from Acros
Organics (Geel, Belgium). Sn(Oct)2, CDCl3 with 1% tetramethylsilane (TMS),
deuterated

dimethyl

sulfoxide

(DMSO-d6),

dimethyl

sulfoxide

(DMSO),

tetrahydrofuran (THF), dichloromethane (DCM), methanol, 2-propanol, hexane,
toluene, and chitosan oligosaccharide lactate (MW = 5,000) were all purchased
from Sigma-Aldrich (St. Louis, MO). Ethyl ether was purchased from J.T. Baker
(Austin, TX). N-Hydroxysuccinimide (NHS) was purchased from Alfa Aesar (Ward
Hill, MA). Acetone was purchased from Pharmco-AAPER (Shelbyville, KY).
Pyridine and hydrochloric acid (HCl) were purchased from EMD (Philadelphia,
PA). Sodium chloride (NaCl) and magnesium sulfate were purchased from
Showa (Tokyo, Japan). All reagents were used as received without further
purification.
3.3.2.

Characterization methods

Gel permeation chromatography (GPC) analyses were performed on a Waters
1525 binary HPLC pump equipped with a Waters 2414 refractive index detector
(Milford, MA). Waters styragel HR 3 (MW = 500 – 30,000) and HR 4E (MW = 50
– 100,000) columns were equipped. Molecular weight calibration was performed
with polystyrene standards that covered a MW range of 400 – 4.3 × 104. GPC
analyses were performed in THF at a flow rate of 1 mL min-1 with an injected
volume of 50 μl. 1H NMR spectra were obtained from a Varian Unity/Inova 400
MHz instrument (Sparta, NJ). To obtain FTIR spectra by a Jasco FTIR-4200
spectrometer (Tokyo, Japan), a small amount of polymeric sample was loaded
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onto a silicon wafer and THF was added dropwise to dissolve the sample and
evaporated afterwards. This was repeated until the entire sample was dissolved
and a film had formed.
3.3.3.

Synthesis of GCV-tagged amphiphilic polymers

G&9 PJ ZDVZHLJKHGDQGPL[HGZLWKİ-CL (2.25 mL) under a sonication
bath for 5 min at room temperature. Sn(Oct)2 ZWRIİ-CL) was then added
into the mixture. The entire solution was placed into a 3-necked round-bottom
flask. The system was purged with nitrogen and immersed in an oil bath at 140oC
for 24 h. The crude product was cooled to room temperature, dissolved in DCM,
and precipitated by cold methanol. The product was then vacuum dried by a
rotary evaporator at 40oC.
GCV-PCL (0.5 mmol) and succinic anhydride (1 mmol) were weighed and
dissolved in toluene in a 3-necked round-bottom flask. One mmol pyridine was
added and the solution was reacted under nitrogen at 70oC for 48 h. The product
was then precipitated by cold hexane, and spun down. The pellet was redissolved in DCM and washed twice each with 10% (v/v) HCl and saturated NaCl
solution. The organic phase was isolated and dried with magnesium sulfate then
filtered. The carboxylated GCV-PCL was recovered by precipitation in cold
hexane and then vacuum dried by rotary evaporation at 40oC.
GCV-PCL-COOH (0.54 mmol) and NHS (2.7 mmol) were weighed and
mixed in 15 mL DCM, and then DCC (2.7 mmol) was added. The reaction was
run under a nitrogen environment at room temperature for 24 h. The precipitated
byproduct 1,3-dicyclohexylurea was removed by vacuum filtration. The filtrate
was added into 35 mL diethyl ether and cooled to 4oC for 4 h to precipitate GCVPCL-NHS. The precipitate was collected by centrifugation at 3,500 rpm for 5 min,
washed with 2-propanol and solvent removed by rotary evaporation at 40oC.
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GCV-PCL-NHS (10 mg) was dissolved in 5 mL acetone and slowly added
to chitosan solution (20 mg chitosan oligosaccharide lactate dissolved in 25 mL
deionized water). The mixture, purged with nitrogen, was stirred in a roundbottom flask for 24 h. The reacted solution was vacuum dried to remove acetone
and then lyophilized. The amphiphilic polymer was then dissolved in DCM and
dialyzed (MWCO = 6-8 kD, Spectra/Por) against pure DCM to remove unreacted
chitosan. ACV-PCL-chitosan was recovered by rotary evaporation at 40oC.
3.3.4.

Preparation of polymeric prodrug micelles

GCV-PCL-chitosan micelles and control MPEG-PCL-chitosan micelles were
formed similarly. Briefly, 10 mg of GCV-tagged amphiphilic polymer was
dissolved in 2 mL acetone. The solution was then added dropwise to 10 mL
deionized water under sonication. Acetone was removed by rotary evaporation
and the final solution was collected by filtering through a 0.45 μm filter.
3.3.5.

Determination of critical micelle concentration

The CMC was estimated by using pyrene as a fluorescent probe [32]. Briefly, 1
mg mL-1 of polymeric prodrug micelle was formed. Various amounts of deionized
water and micellar solution were added respectively to glass vials to obtain
micellar concentrations ranging from 5 × 10-7 to 1 mg mL-1. Pyrene in acetone
was then added separately to the prepared vials to get a final concentration of
pyrene in water of 6.0 × 10-7 mg mL-1, slightly lower than the saturation solubility
of pyrene in water [33]. The solutions were then allowed to equilibrate for 8 h.
Fluorescent spectra were determined by a plate reader (Synergy MX, BioTek,
Winooski, VT) with an excitation wavelength of 334 nm.
3.3.6.

Size and morphology of polymeric prodrug micelles

The average particle size of polymeric prodrug micelles was determined by a
dynamic light scattering (DLS) instrument (Zetasizer Nano ZS, Malvern
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Instruments, United Kingdom) equipped with a red laser at a wavelength of 633
nm and scattering angle of 90o at 25oC. The zeta potential of the micelles
dispersed in deionized water was determined with a zeta potential analyzer
(Zetasizer Nano ZS). Transmission electron microscopy (TEM) image of micelles
was performed on a JEM-4000FX (JEOL, Tokyo, Japan) at 80 kV. The TEM
samples were prepared by adding 10 μL of micellar solution (1 mg mL-1) onto a
Formvar grid for 5 min and wicking away solution in excess. The samples were
negatively stained with 10 μL phosphotungstic acid solution (2 wt%) for 10 sec
and then 15 sec, wicking away excess staining solution each time.
3.3.7.

Drug release kinetics

Polymeric prodrug micelles at a concentration of 1 mg mL-1 were made in
phosphate buffered saline (PBS) (1 M, pH 7.4) at 25oC. Two mL of solution was
placed in a dialysis tube (Float-A-Lyzer, Spectra/Por) with a MWCO of 3.5 – 5
kD. The dialysis bag was then immersed in 50 mL PBS at 37oC with and without
esterase (3 units/2 mL). At specified time intervals, 5 μL of sample was removed
and replaced with fresh PBS. The amount of GCV released was analyzed by a
plate reader (BioTek) at 254 nm. All experiments were carried out in triplicate.
3.3.8.

Establishing TK-overexpressed HT29 cells

Human colorectal HT29 cells (HTB-38; ATCC, Manassas, VA) were plated at a
cell density of 6 x 105, and incubated with 2.5 μL TK plasmid DNA and 5 μL
TransIT-2020 transfection reagent (Mirus, Madison, WI). After 48 h, cells were
trypsinized and suspended in fresh medium containing 400 μg mL-1 G418
antibiotic (Invitrogen, Grand Island, NY). Cells were selected for several weeks
in order to obtain a stable TK overexpressing HT29 cell line (termed HT29/TK).
3.3.9.

Development of GCV-PCL-chitosan/TK nanovectors
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In preparation for one-step delivery of both prodrug and gene to cells, GCV-PCLchitosan/TK nanovectors were prepared. Here, GCV-PCL-chitosan micelles were
prepared as previously described. To 1 mL aliquots of micelle solution various
amounts of TK DNA solution (1.5 – 10.5 μg DNA) was added. The solution was
vortexed briefly and then allowed to incubate at room temperature for 30 min
before DLS and zeta measurements were taken.
3.3.10.

Cytotoxicity studies

24-well plates were seeded with HT29 colorectal cells suspended in 0.5 mL
Dulbecco’s modified Eagles’ medium (DMEM, Corning Cellgro, Manassas, VA)
supplemented with 10% fetal bovine serum (FBS, Atlanta biologicals, Flowery
Branch, GA) and 1% penicillin-streptomycin (Sigma) and incubated at 37oC in 5%
CO2 balanced with humidified air for 24 h. For two-step delivery cytotoxicity
studies, parental HT29 and TK gene transfected HT29 cells (HT29/TK) were
challenged with various concentrations of GCV-PCL-chitosan micelle solution.
Similarly, for one-step cytotoxicity studies, HT29 parental cells were treated with
GCV-PCL-chitosan/TK nanovectors (GCV-PCL-chitosan micelles complexed
with TK gene plasmid). After incubation for 72 h, cell viability was assessed using
MTT assay. 200 μL of sterile MTT solution (4 mg mL-1) was added into the culture
wells and incubated for 4 h. The medium containing unreacted MTT was removed
and 300 μL DMSO was added to dissolve the insoluble purple formazan crystals
formed in cellular mitochondria. The absorbance at 590 nm was measured with
a plate reader (BioTek) and results were recorded as viability percentage
calculated against the control group without micellar challenge. All experiments
were carried out in triplicate.
3.4.
3.4.1.

RESULTS AND DISCUSSION
Synthesis and characterization of amphiphilic prodrug polymers

GCV-PCL was synthesized through ring-opening polymerization of İ-CL
exclusively by GCV (Figure 3.1 A). The 1H NMR spectra of prodrug GCV and
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GCV-PCL are shown in Figure 3.2 (i) and (ii), respectively. &KHPLFDOVKLIWVDWį 
1.37 (3-CH2), 1.62 (2-CH2), 2.27 (1-CH2) and 4.04 (4-CH2) ppm correspond with
WKHEDFNERQHFKDLQRI3&/SRO\PHU3HDNVDWį  H f-CH2), 5.47 (d-CH2)
and 7.76 (b-CH) are assigned to protons in GCV. Evidence of GCV grafting to
PCL is clearly seen by the characteristics resonances observed in the
synthesized polymer, confirming the synthesis of GCV-PCL.

Figure 3.1. Synthetic scheme of (A) GCV-PCL, (B) GCV-PCL-COOH, (C) GCV-PCLNHS, and (D) GCV-PCL-chitosan.

GCV-PCL was further conjugated with chitosan as shown in Figure 3.1 BD. Successful conjugation of chitosan was confirmed by analytical means. Table
3.1, shows the GPC data concerning the formation of amphiphilic copolymer
GCV-PCL-chitosan. The increase in number-average molecular weight (Mn) from
11 kDa to 17 kDa corresponds with the addition of chitosan (MW = 5000).
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Figure 3.2. 1H NMR spectra of (i) GCV and (ii) GCV-PCL.

Table 3.1. Characterization of GCV-PCL-chitosana

a

Sample

Mw
(Da)

Mn
(Da)

Polydispersity
(Mw/Mn)

GCV-PCL

12996

11454

1.13

GCV-PCL-chitosan

20354

17231

1.18

Measured by GPC
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Furthermore, as shown in Figure 3.3, 1H NMR analysis showed successful
conjugation of chitosan to GCV-PCL hydrophobic polymer. As shown in Figure
3.1 D, conjugation of chitosan to GCV-PCL is made via amide linkage. The peak
at 1.79 (A-NH2) from a singlet to a multiplet in Figure 3.3 (iv) confirms conjugation
of chitosan to GCV-PCL. Moreover, the peaks from the aromatic protons on C3 –
C6 of chitosan FDQEHVHHQIURPį – 3.85, slightly shifted downward from
the peaks shown in the original chitosan sample (Figure 3.3 (iii)).

Figure 3.3. 1H NMR spectra of (iii) chitosan and (iv) GCV-PCL-chitosan.

Figure 3.4, depicts the FTIR spectra of GCV-PCL (A), chitosan (B), and
GCV-PCL-chitosan. OH stretching from 3604 – 3167 cm-1 as well as peaks at
1634 cm-1 and 1295 cm-1 corresponding to the N-H bending vibrations of the
primary and secondary amine attributed to chitosan and GCV, respectively. The
aforementioned peaks as well as the carbonyl absorption at 1721 cm-1 associated
with PCL and a peak at 1044 cm-1 (C-O-C) seen in each spectra are found in
GCV-PCL-chitosan. The FTIR results are in line with the results from 1H NMR
and demonstrate successful synthesis of GCV-PCL-chitosan.
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Figure 3.4. FTIR spectra of (A) GCV-PCL, (B) chitosan, and (C) GCV-PCL-chitosan.

3.4.2.

Formation and characterization of GCV-tagged polymeric micelles

Through the solvent evaporation method, polymeric micelles of GCV-PCLchitosan were formed. Here, the hydrophobic core segment was GCV-PCL and
chitosan was the cationic and hydrophilic corona segment. Utilizing pyrene has a
hydrophobic fluorescent probe, the critical micelle concentration (CMC) of GCVPCL-chitosan micelles was examined. Pyrene can preferentially partition into the
interior hydrophobic microdomains and change the intensities of the first and third
bands in the pyrene fluorescence spectrum [33]. A low critical micelle
concentration is indicative that the micellear solution are stable at high dilutions.
For GCV-PCL-chitosan, the shift of the first and third bands was found at I338/I329.
The CMC was determined to be 11.2 mg L-1 (Figure 3.5 A).
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The morphology of GCV-PCL-chitosan micelles was examined through
DLS and TEM analysis. Figure 3.5 (B) shows the size and morphology of GCVtagged polymeric micelles. The average size as reported by DLS was 93.4 nm
with a zeta potential of 38.5 mV. The positive charge is attributed to chitosan used
as the hydrophilic segment on the micelle carriers. TEM analysis are shown in
the insets of Figure 3.5 (B). The size of the micelles in the TEM images was
around 100 nm. The results from DLS and TEM show good agreement.

Figure 3.5. (A) Plot of the intensity ratio (II/IIII) versus concentration of GCV-PCLchitosan micelles and (B) particle size distribution of GCV-PCL-chitosan. Insets
represent TEM images.

After formation of GCV-PCL-chitosan, various concentrations of TK DNA
plasmid was incubated with 1 mL of micelle solution. Due to ionic interactions,
the negatively charged TK DNA was able to form a complex with the positively
charged chitosan used as the hydrophilic segment in micelle nanocarriers. Size
and charge was measured by DLS and the results are shown in Table 3.2. As
can be seen from DLS results, when the DNA was given 30 min to complex with
the micelles, the size of GCV-PCL-chitosan micelles was relatively stable
increasing only to 146 nm with the addition of 10.5 μg TK DNA. Charge began to
decrease from 38.5 mV to 28.2 mV with the addition 0 and 3 μg TK DNA,
respectively. However, after the addition of 4.5, 7.5 and 10.5 μg TK DNA the
charge did not continue to decrease as expected.
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Table 3.2. Size and charge of GCV-PCL-chitosan after addition of TK DNA as measured
by zetasizer
Amount of DNA
(μg)

Size (nm)

Zeta Potential
(mV)

0

93.4

38.5

1.5

92.4

37.9

2

92.4

30.1

3

92.8

28.2

4.5

128.4

37.5

7.5

177.5

35.0

10.5

146

33.9

To determine the drug loading percentage of GCV per mg of prepared
micelle solution, the absorbance of GCV-PCL-chitosan was examined at t = 0
and t = 72 h and compared to a standard calibration curve of GCV ranging from
0.002 to 1.0 mg mL-1. It was found that GCV comprised 4.8% of the micelles.
3.4.3.

In vitro release of GCV from polymeric micelles

The in vitro release behavior of GCV at 37oC with and without esterase was
studied. To mimic cellular conditions, esterase at a concentration of 3 units/2 mL
was used [34]. As can be seen from Figure 3.6, the release of GCV with esterase
was much quicker than without reaching a maximum release of 81% within 30 h.
In contrast it took 48 h without esterase for GCV to reach a maximum release of
77% (Figure 3.7). Moreover, it took up to 2 h before a substantial difference in
the release rate was seen. This is due to the time needed for esterase to diffuse
into the micelle core and for activation.
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Figure 3.6. In vitro drug release profile of GCV from GCV-PCL-chitosan in PBS at
37oC with esterase (3 units/ 2 mL) (mean ± SD, n = 3).

The release of GCV from GCV-PCL-chitosan was modeled using both
Power Law and Langmuir models. As can be seen from Figure 3.6 and 3.7, Power
Law was not a good fit for the release of GCV from polymeric micelles. Here, the
exponent, n, was equal to 0.18 and 0.29 in GCV-PCL-chitosan micelles with and
without esterase, respectively. Similar to the release of ACV in Chapter 2, the
drug release mechanism does not occur solely though diffusion [35]. Here,
without esterase, GCV release will occur by hydrolysis of the ester bond. The
release rate is increased by the addition of esterase to GCV-PCL-chitosan which
in addition to hydrolysis will break the ester bond. Due to the fact that GCV
release occurs through reactive diffusion, the Langmuir model was also chosen
for fitting the data. As can be seen in Figure 3.6 and 3.7, the release of GCV from
GCV-PCL-chitosan with and without esterase using the Langmuir model fits the
experimental data well. In addition, the dissociation constant (Kd) for release of
GCV from GCV-PCL-chitosan, was found to be 1.18 and 2.79 with and without
esterase, respectively. Relating this data to the release of ACV in Chapter 2 leads
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to several conclusions. First, GCV has a stronger association to PCL then ACV
(K = 2.79 and 1.14, respectively). Secondly, the addition of esterase will increase
the release rate to a similar release to ACV. We hypothesized that the increase
in the dissociation constant was due to GCV having two reactive points to initiate
ring-opening polymerization of ɸ-CL compared to ACV which only has one. In our
results with 5’DFUR (Chapter 3), a similar trend to GCV release was seen,
confirming our hypothesis.
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Figure 3.7. In vitro drug release profile of GCV-PCL-chitosan in PBS at 37oC (mean
± SD, n = 3).

3.4.4.

Cytotoxicity studies

To examine the potential of GCV for suicide gene therapy, HT29 colorectal cells
were transfected with HSV-TK gene plasmid. The growth of both parental HT29
and HT29/TK cells are shown in Figure 3.8. It can be seen that the growth kinetics
revealed that both HT29 and HT29/TK cells followed a similar growth rate after
transfection and selection of a stable transfected cell line was not altered.
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Figure 3.8. Cell growth kinetics profiles of HT29 (

After obtaining a stable transfected cell line, HT29 and HT29/TK cells were
challenged with GCV-tagged polymeric prodrug micelles. Through MTT assay,
cytotoxicity of GCV-PCL-chitosan polymeric micelles ranging in centration of 25
to 250 μg mL-1 for 24, 48 and 72 h were investigated. Due to the fact that parental
HT29 cells do not have any endogenous TK gene plasmid to convert GCV to its
toxic form, cell viability was not affected (Figure 3.9 A). In contrast, HT29/TK cells
which had upregulated TK gene expression showed cell death up to 35% at a
dosage of 250 μg mL-1 for 72 h treatment (Figure 3.9 B). These results confirmed
that GCV can be converted to its active and toxic form via overexpressed TK
gene in colon cancer cells for the classical two-step treatment.
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Figure 3.9. Cell viability after treatment with GCV-PCL-chitosan micelles (A)
parental HT29, and (B) HT29/TK cells.
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In an effort to examine the feasibility of a one-step anticancer therapy, TK
DNA (1.5 and 6 μg) was complexed onto GCV-PCL-chitosan micelles via ionic
interactions. Here, expression of the gene plasmid and subsequent toxicity was
followed for three days and five days. As can be seen in Figure 3.10, expression
of the plasmid in the cells after three days was sufficient to cause cell death. An
additional two days did not cause a significant increase in cell toxicity. Moreover,
it was seen that when TK gene plasmid was complexed onto control micelles
(MPEG-PCL-chitosan), no cell toxicity was observed. These observations are
expected because the micelle alone is not toxic to the cells, it is the prodrug GCV
converted to its cytotoxic form by HSV-TK which causes cell death. From these
results, subsequent one-step studies were carried out with 3 days for gene
expression and subsequent toxicity.
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Figure 3.10. Expression of HSV-TK gene plasmid. 1.5 and 6 μg HSV-TK DNA was
complexed onto GCV-PCL-chitosan and MPEG-PCL-chitosan micelles and the
gene expression followed for 3 (
) and 5 (
) days.
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After expression studies, parental HT29 cells were then treated with
various concentrations of GCV-PCL-chitosan/TK nanovectors complexed with
1.5 - 10.5 μg TK DNA and cytotoxicity observed as shown in Figure 3.11. Toxicity
followed a similar trend to what was expected. By increasing the amount of DNA,
there is more conversion of GCV to its cytotoxic form and therefore, more cell
death. In this study, cell viability was decreased to around 52% with a micelle
concentration of 250 μg mL-1 and 4.5 μg DNA. It appears that 4.5 μg TK DNA is
the upper limit for DNA complexation with GCV-PCL-chitosan micelles.
Increasing the TK DNA amounts to 7.5 and 10.5 μg did not show an increase in
cell death.
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Figure 3.11. One-step delivery of gene and prodrug. Parental HT29 cells were
challenged with 250 (
), 75 (
), and 25 (
) μg mL-1 GCV-PCL-chitosan/TK
nanovectors for 3 days.
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3.5.

CONCLUSION

GDEPT is a promising gene therapy method to combat cancer. However,
developing an efficient carrier for both the gene and prodrug required for
enhanced cancer therapy. In this study, we have developed a micelle carrier
which achieved both of these goals, sufficient gene and prodrug delivery.
Moreover, our polymer micelle carriers deliver both the gene and prodrug
simultaneously, which is ideal for patients. Our results indicate that GCV-PCLchitosan nanocarriers can reduce viability of HT29 colorectal cells by 52% in a
one-step approach. Developing similar drug nanocarriers could have broad
impact and enhance the effectiveness of GDEPT.
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CHAPTER 4:

ENHANCED

5’DFUR-PCL-MPEG

ANTICANCER

POLYMERIC

ACTIVITY

PRODRUG

OF

MICELLES

ENCAPSULATING CHEMOTHERAPEUTIC DRUGS4
4.1.

ABSTRACT

In this study, chemotherapy prodrug 5-doxifluridine (5’-DFUR) associated with
amphiphilic copolymHU SRO\ İ-caprolactone)-methoxy poly(ethylene glycol) (5’DFUR-PCL-MPEG) was synthesized, characterized, and self-assembled into
functional polymeric micelles. To demonstrate that prodrug 5’-DFUR could
convert

into

cytotoxic

5-fluorouracil

(5-FU)

by

endogenous

thymidine

phosphoylase (TP), HT29 colon cancer cells were treated with 5’-DFUR-PCLMPEG polymeric micelles for various time periods and showed up to 40% cell
death rate after 72 h treatment. In contrast, HT29 cells challenged with 5’-DFURtagged polymeric micelles which encapsulated DOX or SN-38, chemotherapeutic
drugs, remained only 36% and 31% in cell viability. Our results demonstrated that
the developed 5’-DFUR-PCL-MPEG polymeric micellar nanoparticles have the
potential for gene-directed enzyme prodrug therapy.
4.2.

INTRODUCTION

5-Fluorouracil (5-FU) is one of the main anti-tumor agents used to treat colon,
breast and gastric cancers. Due to the short plasma half-life of 5-FU, it is often
administered to patients through continuous infusion [1]. 5-FU however, is poorly
tumor selective and its therapy causes several severe adverse side effects in
patients including intestinal discomfort. To circumvent toxicity, 5-doxifluridine (5’DFUR), a prodrug of 5-FU, is commonly administered to patients [2]. 5’-DFUR is
converted to its active and toxic form 5-FU through metabolic conversion by
thymidine phosphorylase (TP), a gene overexpressed in many cancer types [3].
Several groups have exploited the enzyme-prodrug activation model of TP and
4

The material contained in this chapter is planned for publication in The Journal of
Controlled Release.
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5’-DFUR and shown that by transfection of cancer cell lines with TP, sensitivity
of tumor cells to this prodrug is enhanced by the increased TP expression [4, 5].
Clinically, 5’-DFUR has been established for treatment of various cancer
types [6-8]. Moreover, several studies have evaluated combination therapies of
5’-DFUR

with

other

chemotherapy

drugs

such

as

tamoxifen,

medroxyprogesterone acetate, and docetaxel with successful results [9-11].
While 5’-DFUR itself is slightly hydrophilic, intrinsic issues that are associated
with other “free drugs,” such as poor solubility, unwanted toxicity, and short
circulation times have propelled research into alternative drug delivery systems.
There are several factors which contribute to success of a synthesized
therapeutic carrier. One must first address the physiochemical limitations of the
drugs; second, one needs to address the biological hurdles in reaching the
targeted tumorous tissue. Polymeric nanocarriers for drug delivery are being
developed for a wide variety of cancers and chemotherapeutic drugs [12-14].
Specifically, several polymeric micelle carriers which house hydrophobic
chemotherapy

drugs

doxorubicin

(DOX),

paclitaxel

or

7-ethyl-10-

hydroxycamptothecrin (SN-38) in their core are advancing into clinical trials with
great success [15-17].
SN-38 is a biologically active metabolite of irinotecan hydrochloride (CPT11). While CPT-11 is a prodrug which can be converted to SN-38 by
carboxylesterases, SN-38 has shown to have 1,000-fold more potent toxicity
towards various cancer cells in vitro [18]. Moreover, metabolic conversion of
CPT-11 to SN-38 in the liver and tumor has shown to be less than 10% of its
original volume [19, 20]. Therefore, direct use of SN-38 is advantageous for
cancer treatment. Similarly, DOX is another widely used antitumor drug effective
in the treatment of carcinomas of the breast, lung, thyroid and colon. However,
due to the ensuing toxicity and low water solubility of free SN-38 and DOX, use
of a drug carrier is warranted.
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It has been shown previously that the hydroxyl groups on 5’DFUR can be
used for initiation in the ring-RSHQLQJ SRO\PHUL]DWLRQ RI İ-caprolactone to form
hydrophobic

5’-DFUR-polycaprolactone

(5’-DFUR-PCL)

[21]

3RO\ İ-

caprolactone) (PCL) is commonly used for biomedical applications because of its
excellent biodegradability and biocompatibility [22]. In this study, we further
grafted hydrophobic 5’-DFUR-PCL with hydrophilic biodegradable methoxy
poly(ethylene glycol) MPEG, widely used for drug delivery to form amphiphilic
copolymers for micelle preparation [23-25]. Moreover, because camptothecinbased drugs are often used in conjunction with 5-FU as a first therapy [26], and
the anticancer effectiveness of DOX, we encapsulated SN-38 or DOX into our
prodrug-tagged polymeric micelles for an additive anticancer therapy.
To evaluate anticancer effectiveness of our synthesized polymeric micelle
carriers, HT29 colon cancer cells, which express endogenous TP levels, were
treated with our micelle carrier. Moreover, SN-38 and DOX, chemotherapeutic
drugs, used to treat a wide variety of cancer types, were encapsulated into our
micelle carriers and the additive effect of both 5’DFUR and chemotherapeutic
drugs on HT29 cell death was examined. Our results indicate that 5’-DFUR-PCLMPEG micelle carriers are an effective and efficient means to deliver 5’DFUR
and chemotherapeutic drugs to tumor cells.
4.3.
4.3.1.

MATERIALS AND METHODS
Materials

5’-DFUR was purchased from Tokyo Chemical Industry Co. Ltd. (TCI, Japan).
N,N’-GLF\FORKH[\O FDUERGLLPLGH '&&  İ-CL, pyrene, and succinic anhydride
were purchased from Acros Organics (Geel, Belgium). Sn(Oct)2, CDCl3 with 1%
tetramethylsilane (TMS), deuterated dimethyl sulfoxide (DMSO-d6), dimethyl
sulfoxide (DMSO), tetrahydrofuran (THF), dichloromethane (DCM), methanol, 2propanol, hexane, toluene, SN-38, DOX, methoxypolyethylene glycol amine
(MPEG-NH2; MW = 5,000), and MPEG (MW = 350) were all purchased from
Sigma-Aldrich (St. Louis, MO). Ethyl ether was purchased from J.T. Baker
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(Austin, TX). N-Hydroxysuccinimide (NHS) was purchased from Alfa Aesar (Ward
Hill, MA). Acetone was purchased from Pharmco-AAPER (Shelbyville, KY).
Pyridine and hydrochloric acid (HCl) were purchased from EMD (Philadelphia,
PA). Sodium chloride (NaCl) and magnesium sulfate were purchased from
Showa (Tokyo, Japan). All reagents were used as received without further
purification.
4.3.2.

Characterization methods

Gel permeation chromatography (GPC) analyses were performed on a Waters
1525 binary HPLC pump equipped with a Waters 2414 refractive index detector
(Milford, MA). Waters styragel HR 3 (MW = 500 – 30,000) and HR 4E (MW = 50
– 100,000) columns were equipped. Molecular weight calibration was performed
with polystyrene standards that covered a MW range of 400 – 4.3 × 104. GPC
analyses were performed in THF at a flow rate of 1 mL min-1 with an injected
volume of 50 μl. 1H NMR spectra were obtained from a Varian Unity/Inova 400
MHz instrument (Sparta, NJ). To obtain FTIR spectra by a Jasco FTIR-4200
spectrometer (Tokyo, Japan), a small amount of polymeric sample was loaded
onto a silicon wafer and THF was added dropwise to dissolve the sample and
evaporated afterwards. This was repeated until the entire sample was dissolved
and a film had formed.
4.3.3.

Synthesis of 5’DFUR-tagged amphiphilic polymers

5’DFUR PJ ZDVZHLJKHGDQGPL[HGZLWKİ-CL (2.25 mL) under a sonication
bath for 5 min at room temperature. Sn(Oct)2 ZWRIİ-CL) was then added
into the mixture. The entire solution was placed into a 3-necked round-bottom
flask. The system was purged with nitrogen and immersed in an oil bath at 140oC
for 24 h. The crude product was cooled to room temperature, dissolved in DCM,
and precipitated by cold methanol. The product was then vacuum dried by a
rotary evaporator at 40oC.
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5’DFUR-PCL (0.5 mmol) and succinic anhydride (1 mmol) were weighed
and dissolved in toluene in a 3-necked round-bottom flask. One mmol pyridine
was added and the solution was reacted under nitrogen at 70oC for 48 h. The
product was then precipitated by cold hexane, and spun down. The pellet was redissolved in DCM and washed twice each with 10% (v/v) HCl and saturated NaCl
solution. The organic phase was isolated and dried with magnesium sulfate then
filtered. The carboxylated 5’DFUR-PCL was recovered by precipitation in cold
hexane and then vacuum dried by rotary evaporation at 40oC.
5’DFUR-PCL-COOH (0.54 mmol) and NHS (2.7 mmol) were weighed and
mixed in 15 mL DCM, and then DCC (2.7 mmol) was added. The reaction was
run under a nitrogen environment at room temperature for 24 h. The precipitated
byproduct 1,3-dicyclohexylurea was removed by vacuum filtration. The filtrate
was added into 35 mL diethyl ether and cooled to 4oC for 4 h to precipitate
5’DFUR-PCL-NHS. The precipitate was collected by centrifugation at 3,500 rpm
for 5 min, washed with 2-propanol and solvent removed by rotary evaporation at
40oC.
5’DFUR-PCL-NHS (10 mg) and MPEG-NH2 (10 mg) were weighed and
dissolved by 20 mL DCM in a round-bottom flask. The flask was purged with
nitrogen and the solution was stirred for 24 h. The solution was then dialyzed
(MWCO = 6-8 kD, Spectra/Por, Rancho Dominguez, CA) against pure DCM to
remove remaining MPEG-NH2. 5’DFUR-PCL-MPEG was recovered by rotary
evaporation at 40oC.
4.3.4.

Preparation of polymeric prodrug micelles

5’DFUR-PCL-MPEG and chemotherapy drug loaded 5’DFUR-PCL-MPEG
micelles were formed similarly. Briefly, 10 mg of 5’DFUR-tagged amphiphilic
polymer, with or without 0.2 mg DOX or 0.1 mg SN-38, were dissolved in 2 mL
acetone under bath sonication. The solution was then added dropwise to 10 mL
deionized water under bath sonication. Acetone was removed by rotary
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evaporation and the final solution was collected by filtering through a 0.45 μm
filter.
4.3.5.

Determination of critical micelle concentration

The critical micelle concentration (CMC) was estimated by using pyrene as a
fluorescent probe [27]. Briefly, 1 mg mL-1 of polymeric prodrug micelle was
formed. Various amounts of deionized water and micellar solution were added
respectively to glass vials to obtain micellar concentrations ranging from 5 × 10-7
to 1 mg mL-1. Pyrene in acetone was then added separately to the prepared vials
to get a final concentration of pyrene in water of 6.0 × 10-7 mg mL-1, slightly lower
than the saturation solubility of pyrene in water [28]. The solutions were then
allowed to equilibrate for 8 h. Fluorescent spectra were determined by a plate
reader (Synergy MX, BioTek, Winooski, VT) with an excitation wavelength of 334
nm.
4.3.6.

Size and morphology of polymeric prodrug micelles

The average particle size of polymeric prodrug micelles was determined by a
dynamic light scattering (DLS) instrument (Zetasizer Nano ZS, Malvern
Instruments, United Kingdom) equipped with a red laser at a wavelength of 633
nm and scattering angle of 90o at 25oC. The zeta potential of the micelles
dispersed in deionized water was determined with a zeta potential analyzer
(Zetasizer Nano ZS). Transmission electron microscopy (TEM) image of micelles
was performed on a JEM-4000FX (JEOL, Tokyo, Japan) at 80 kV. The TEM
samples were prepared by adding 10 μL of micellar solution (1 mg mL-1) onto a
Formvar grid for 5 min and wicking away solution in excess. The samples were
negatively stained with 10 μL phosphotungstic acid solution (2 wt%) for 10 sec
and then 15 sec, wicking away excess staining solution each time.
4.3.7.

Drug loading content and entrapment efficiency
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To determine the drug loading percentage of 5’DFUR per mg of micelle
formulation, the absorbance of 5’DFUR-PCL-MPEG micelles at t=0 and t=72 h
was examined Ȝ %LR7HN and compared to a standard calibration curve of
5’DFUR ranging from 0.002 to 1.0 mg mL-1. To obtain drug loading content and
entrapment efficiency of DOX or SN-38 encapsulated in micelles, the obtained
micellear solutions were frozen and lyophilized by a freezer dryer system to
obtain dried nanoparticle product. The weighed nanoparticles were dissolved in
chloroform/DMSO (1:1, v/v) and the absorbance of the solutions read at 485 nm
(DOX) or 366 nm (SN-38) using a plate reader. The weight of the entrapped drug
was calculated by a calibration curve from 0.01 mg mL-1 to 1 mg mL-1. Drug
loading content and entrapment efficiency were determined by equations (1) and
(2), respectively:

4.3.8.

Drug loading content (%) =

weight of drug in nanoparticles
× 100
weight of nanoparticles

(1)

Entrapment efficiency (%) =

weight of drug in nanoparticles
× 100
weight of drug fed initially

(2)

Drug release kinetics

Polymeric prodrug micelles at a concentration of 1 mg mL-1 were made in
phosphate buffered saline (PBS) (1 M, pH 7.4) at 37oC. 2 mL of solution was
placed in a dialysis tube (Float-A-Lyzer, Spectra/Por) with a MWCO of 3.5 – 5
kD. The dialysis bag was then immersed in 50 mL PBS at room temperature and
370C with and without esterase (3 units/2 mL) to mimic cellular conditions. At
specified time intervals, 5 μL of sample was removed and replaced with fresh
PBS. The amount of 5’DFUR released was analyzed by a plate reader (BioTek)
at 269 nm. All experiments were carried out in triplicate.
4.3.9.

Cytotoxicity studies

24-well plates were seeded with human colorectal HT29 cells (HTB-38; ATCC,
Manassas, VA) suspended in 0.5 mL Dulbecco’s modified Eagles’ medium
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(DMEM, Corning Cellgro, Manassas, VA) supplemented with 10% fetal bovine
serum (FBS, Atlanta biologicals, Flowery Branch, GA) and 1% penicillinstreptomycin (Sigma) and incubated at 37oC in 5% CO2 balanced with humidified
air for 24 h. In one well, 1 mL of 2 mg mL-1 of polymeric micelle solution (filtered
by a 0.45 μm filter) was added. Serial dilutions were preformed to a final
concentration of 0.25 mg mL-1. After incubation for 72 h, cell viability was
assessed using MTT assay. 200 μL of sterile MTT solution (4 mg mL-1) was
added into the culture wells and incubated for 4 h. The medium containing
unreacted MTT was removed and 300 μL DMSO was added to dissolve the
insoluble purple formazan crystals formed in cellular mitochondria. The
absorbance at 590 nm was measured with a plate reader (BioTek) and results
were recorded as viability percentage calculated against the control group without
micellar challenge. All experiments were carried out in triplicate.
4.4.
4.4.1.

RESULTS AND DISCUSSION
Synthesis and characterization of amphiphilic prodrug polymers

Figure 1 A-D describes the preparation of 5’DFUR-PCL-MPEG copolymer. First,
5’DFUR-PCL was directly synthesized via the ring-RSHQLQJSRO\PHUL]DWLRQRIİCL initiated by 5’DFUR as previously reported [21]. 1H NMR spectra of prodrug
5’DFUR and 5’DFUR-PCL post synthesis are shown in Figure 4.2 (i) and (ii),
respectively. Characteristic resonance peaks associated with 5’-DFUR including
į  J-CH3), 4.20 (f-CH), 5.02 (e-CH), 5.25 (d-CH), 5.95 (c-CH), and 7.97
(b-CH) ppm were seen in synthesized 5’-DFUR-PCL. Chemical shifts associated
with PCL were seen at 1.40 (3- CH2), 1.65 (2-CH2), 2.34 (1-CH2), 3.62 (4’-CH2),
and 4.05 (4-CH2) ppm. These spectra demonstrated evidence of ring-opening
SRO\PHUL]DWLRQ RI İ-CL by prodrug 5’-DFUR. GPC data concerning the
polymerization of PCL by 5’DFUR is given in Table 4.1, accordingly, the number
average molecular weight (Mn) of 5’DFUR-PCL polymer was approximately 15
kDa with a polydispersity index (PDI) of 1.24.
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Figure 4.1. Synthetic scheme of (A) 5’DFUR-PCL, (B) 5’DFUR -PCL-COOH, (C)
5’DFUR -PCL-NHS, and (D) 5’DFUR -PCL-MPEG.

Hydrophobic 5’DFUR-PCL was further grafted with MPEG (MW=5,000) as
shown in Figure 4.1 B-D. GPC analysis revealed that 5’DFUR-PCL-MPEG
amphiphilic copolymer had a Mn of 28 kDa and PDI of 1.19 (Table 4.1). Figure
4.3 (iii) and (iv), shows the 1H NMR of MPEG-NH2 and 5’DFUR-PCL-MPEG. The
peaks at 3.63 (A-OCH2) attributed to MPEG can be clearly seen in Figure 4.3 (iv).
Due to the conjugation of MPEG to 5’DFUR-PCL through amide linkage (Scheme
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4.1 D), the change of the peak at 1.79 (B-NH2) from a singlet in Figure 4.3 (iii) to
a multiplet in Figure 4.3 (iv) further confirms conjugation of MPEG to hydrophobic
5’DFUR-PCL. Further characterization of successful grafting of MPEG to
hydrophobic 5’DFUR-PCL was examined through FTIR analysis.

Figure 4.2. 1H NMR spectra of (i) 5’DFUR and (ii) 5’DFUR-PCL.

FTIR was employed to show the successful grafting of MPEG to 5’-DFURPCL-NHS (Scheme 4.1 D). FTIR spectra of 5’DFUR-PCL (A), MPEG-NH2 (B) and
5’DFUR-PCL-MPEG (C) are shown in Figure 4.4. C-H stretching vibrations can
be seen from 2957-2839 cm-1 for all samples. Typical FTIR absorption peaks of
PCL and MPEG at 1721 cm-1 attributed to the C=O stretching and at 1103 cm-1
of the C-O-C, respectively, were seen in the FTIR spectra. These peaks, as well
as characteristic peaks contributed from 5’-DFUR such as C-F stretching at 1049
cm-1, C-N stretching of the primary and secondary aromatic amine at 1627 and
1237 cm-1 were all found in Figure 4.4 (A) and (C). Showing successful initiation
of polymerization of ɸ-CL by 5’DFUR.
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Figure 4.3. 1H NMR spectra of (iii) MPEG and (iv) 5’DFUR-PCL-MPEG.

Figure 4.4. FTIR spectra of (A) 5’DFUR-PCL, (B) MPEG-NH2, and (C) 5’DFUR-PCLMPEG.
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Table 4.1. Characterization of 5’DFUR-PCL-MPEG amphiphilic copolymera
Mw
Polydispersity
Mn
Sample
(Da)
(Mw/Mn)
(Da)
5’DFUR-PCL
18796
15158
1.24

a

5’DFUR-PCL-MPEG

33927

28510

1.19

MPEG350-PCL

24600

17053

1.44

MPEG350-PCL-MPEG

19415

21624

1.36

Measured by GPC

4.4.2. Formation and characterization of 5’DFUR-tagged polymeric micelles
It is known that amphiphilic polymers can self-assemble into micelles in selected
solvent. The amphiphilic 5’DFUR-PCL-MPEG copolymer used in this study, could
self-assemble into micelles in aqueous solution by the solvent-evaporation
method. Here, despite 5’DFUR being slightly water soluble, 5’DFUR-PCL was
the hydrophobic core segment and MPEG was the hydrophilic outside shell. In
control micelles, MPEG350-PCL was the hydrophobic core segment and MPEG
was the hydrophilic segment. The average size of 5’DFUR-tagged micelles and
control micelles with and without encapsulating DOX or SN-38 and zeta potential
as determined by dynamic light scattering (DLS) and zetasizer are shown in
Table 4.2. The size of 5’DFUR-PCL-MPEG micelles was around 220.5 nm with a
zeta potential of 1.2 mV due to the neutral change of MPEG (Figure 4.5 (A)).
Micelles were also characterized by TEM analysis as shown in the Figure 4.5
inset. The size of the micelles in the TEM images was slightly lower than the
results from DLS with an average particle size of ~150 nm. This size fluctuation
is due to the fact that DLS records the hydrodynamic radius of particles which is
often times slightly larger than the actual particle size. As shown in Table 4.2,
encapsulation of DOX or SN-38 did not affect the particle size substantially with
an average size of 167.5 and 267.5 nm, respectively.
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Table 4.2. Characteristics and drug loading of 5’DFUR-tagged polymeric micelles
Drug loading Entrapment
Size
Zeta
content
efficiency
Sample
(nm)
(mV)
(%)
(%)
5’DFUR-PCL-MPEG

220.5

1.23

--

--

5’DFUR-PCL-MPEG
(DOX)

167.5

-0.11

10.8

68.8

5’DFUR-PCL-MPEG
(SN-38)

267.5

1.01

3.4

86.3

MPEG350-PCL-MPEG

202.5

0.74

--

--

MPEG350-PCL-MPEG
(DOX)

222

2.15

10.4

65.6

MPEG350-PCL-MPEG
(SN-38)

148

1.21

3.9

97.6

The CMC of 5’DFUR-PCL-MPEG was determined using pyrene as a
hydrophobic florescent probe to confirm formation of micellear structures [28].
Figure 4.5 B shows the CMC value of 5’DFUR-tagged polymeric micelles in

Figure 4.5. (A) Particle size distribution, and (B) plot of the intensity ratio (II/IIII) versus
concentration of 5’DFUR-PCL-MPEG micelles. Inset represents TEM image.
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aqueous medium. The intensity ratio of the first and third vibrational bands
(I338/I335) against polymer concentration (Log(concentration)) in pyrene excitation
spectra was plotted. A flat region in the low concentration extreme and sigmoidal
region in the crossover region was found, and the CMC of 5’DFUR-tagged
micelles was 56 mg L-1.
4.4.3 Evaluation of drug loading content and entrapment efficiency
Table 4.2 summarizes the drug loading content and entrapment efficiency of
5’DFUR, DOX, and SN-38 in both 5’DFUR-tagged polymeric micelles and control
micelles. To determine the drug loading percentage of 5’DFUR per mg of micelle
formulation, the absorbance of 5’DFUR before and after drug release (t=0, t=72
h) was examined and compared to a standard calibration curve of 5’DFUR. It was
found that 5’DFUR comprised 9.8% of 5’DFUR-PCL-MPEG micelles. Due to the
hydrophobic nature of SN-38, it was surmised that the extent of drug loading and
entrapment would be high. As can be seen in Table 4.2, our results showed that
the drug loading content and entrapment efficiency of SN-38 in 5’DFUR-PCLMPEG and control micelles was 3.4% and 86.3% and 3.9% and 97.6%,
respectively. In contrast, DOX which is slightly hydrophilic had a lower
encapsulation efficiency at 68.8% and 65.6% in prodrug-tagged polymeric
micelles and control micelles, respectively. However, due to the fact that more
DOX was used for encapsulation, the drug loading content was higher at 10.8%
and 10.4% It is known that drug encapsulation efficiency is a crucial design
parameter in the development of therapeutic nanocarriers. An ideal nano-carrier
should have a high drug encapsulation efficiency and small size to evade the
MPS. The synthesized 5’DFUR-tagged micelles developed here exhibit both of
these qualities.
4.4.4. In vitro drug release
The in vitro release behavior of 5’DFUR both at 37oC with and without esterase
was studied and the results are shown in Figure 4.6 A and B, respectively. To
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mimic cellular conditions, esterase at a concentration of 3 units/2 mL was chosen
[29]. A two-phase release profile was observed in all conditions with a burst
release within the first 2 h followed by sustained release pattern up to 72 h. It was
found that it required 2 h before esterase was able to increase the release of
5’DFUR. This observation is in line with other researchers due to the fact that
esterase has to take time to diffuse into the micelle and to activate [30, 31]. The
release of 5’DFUR in samples without esterase was caused by hydrolysis of ester
linkage between 5’DFUR and PCL. It is surmised that the sustained release of
5’DFUR compared to previously reported prodrug release is due to that fact that
polymerization can be initiated at two hydroxyl points [32]. Accumulative release
of each sample reached a maximum between 78-86%.

Figure 4.6. In vitro drug release profile of 5’DFUR from 5’DFUR-PCL-MPEG micelles
in PBS at 37oC (A) with esterase, (B) without esterase (mean ± SD, n = 3).

The release of 5’DFUR from 5’DFUR-PCL-MPEG was modeled using both
Power Law and Langmuir models as shown in Figure 4.6 A and B. The Power
Law model was not a good fit for the release of 5’DFUR from polymeric micelles.
Here, we obtained an exponent, n, value equal to 0.24 and 0.30 with and without
esterase, respectively. If n is 0.43, for a sphere, this would indicate Fickian
diffusion [33]. Due to the fact that our release is not solely though diffusion (i.e.
5’DFUR is chemically bound to PCL though ester bond), our release is reaction
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diffusion. Here, the prodrug 5’DFUR, is released through hydrolysis (Figure 4.6
B) or a combination of hydrolysis and esterase (Figure 4.6 A). Therefore, we
chose to also model our data with the Langmuir model. The Langmuir model is
an enzyme kinetics model, and as can be seen in Figure 4.6, a good fit for the
release of 5’DFUR from polymeric micelles. The dissociation constant (Kd) for the
release of 5’DFUR from 5’DFUR-PCL-MPEG was found to be 1.48 and 3.07 with
and without esterase, respectively. Similar to the release of GCV in Chapter 3,
our K value was higher when esterase was not added showing that the
association of 5’DFUR to PCL is stronger than ACV (Chapter 2). We speculate
that this stronger association is due to the fact that 5’DFUR, like GCV, has two
reactive points to initiate polymerization of ɸ-CL.
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Figure 4.7. In vitro drug release profiles of DOX and SN-38 from 5’DFUR-PCLMPEG micelles in PBS at 37oC (mean ± SD, n = 3).

The release of DOX and SN-38 at 37oC in 5’DFUR-PCL-MPEG is shown
in Figure 4.7. The release profiles showed that a cumulative release of DOX and
SN-38 from 5’DFUR-tagged micelles in PBS at 37oC was 87% and 62%,
respectively, after 48 h. Moreover, we modeled the data using the Power Law
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and it was found to be a good fit for both of the encapsulated chemotherapeutic
drugs. For the release of DOX and SN-38, we obtained n values of 0.41 and 0.43.
These values are very close to the exponent value n (0.43) for the Fickian
diffusion of a sphere. Indicating that Fickian diffusion is most likely the release
mechanism for encapsulated chemotherapy drugs DOX and SN-38.
4.4.5.

Cytotoxicity of 5’DFUR-tagged polymeric micelles loaded with
chemotherapeutic agents

In vitro toxicity of polymeric prodrug micelles to parental HT29 cells was
evaluated. Due to the fact that HT29 cells express endogenous TP levels [34],
5’DFUR released from micelles would be converted to its active and toxic form 5FU. Figure 4.8 compares the viability of control micelles and 5’DFUR-PCL-MPEG
micelles. Here, it can be seen that micelles without prodrug are nontoxic up to a
concentration of 2 mg mL-1 (Figure 4.8 A). In contrast, the viability of HT29 cells
is decreased to 60% when challenged with 2 mg mL-1 5’DFUR-PCL-MPEG
micelles for 72 h (Figure 4.8 B). Moreover, it is shown that a concentration of
5’DFUR-tagged micelle greater than or equal to 0.5 mg mL-1 is needed for cell
death to occur. For this reason subsequent cytotoxicity studies with
chemotherapeutic drugs DOX and SN-38 were not evaluated below 0.5 mg mL1.
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A

B

Figure 4.8. Cell viability of HT29 cells after treatment with polymeric micelles for
24, 48, and 72 h. (A) MPEG-PCL-MPEG polymeric micelles, (B) 5’DFUR-PCLMPEG polymeric micelles.
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As can be seen from Figure 4.9 and Figure 4.10, HT29 cell viability was
decreased in both control (A) and prodrug-tagged micelles with encapsulated
chemotherapy drug (B). Control micelles without chemotherapy drug, showed
little to no toxicity (Figure 4.8 A), after the encapsulation of DOX or SN-38 into
MPEG-PCL-MPEG micelles, viability was reduced to 53% and 43%, respectively,
with the highest dose for 72 h (Figure 4.9 A and Figure 4.10 A). Toxicity of HT29
cells treated with 5’DFUR-PCL-MPEG micelle with encapsulated DOX showed
an increased cell death from 60% viability without DOX to 36.6% viability (Figure
4.9 B). This corresponds to an additive effect from both 5’DFUR converted to 5FU by endogenous TP gene plasmid and DOX chemotherapy drug. The toxicity
of 5’DFUR-tagged micelles which encapsulated SN-38 was also increased from
60% cell viability to 31% again showing an additive effect between 5’DFUR and
chemotherapy drug SN-38 in cancer cell treatment. The results of cell viability
show that delivery of 5’DFUR-tagged polymeric micelles can decrease viability of
HT29 cells and that encapsulation of chemotherapy drugs can substantially
increase cell death.
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Figure 4.9. Cell viability of HT29 cells after treatment with polymeric micelles
encapsulating DOX for 24, 48, and 72 h. (A) MPEG-PCL-MPEG polymeric
micelles, (B) 5’DFUR-PCL-MPEG polymeric micelles.
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Figure 4.10. Cell viability of HT29 cells after treatment with polymeric micelles
encapsulating SN-38 for 24, 48, and 72 h. (A) MPEG-PCL-MPEG polymeric
micelles, (B) 5’DFUR-PCL-MPEG polymeric micelles.
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4.5.

CONCLUSION

The results of this study show that 5’DFUR-PCL-MPEG micelles were
synthesized and characterized. Moreover, results showed that polymeric micelles
of 5’DFUR-PCL-MPEG successfully delivered prodrug into HT29 colon cancer
cells and it was clearly revealed that endogenous TP in parental HT29 colon
cancer cells could convert prodrug 5’DFUR into cytotoxic 5-FU thereby killing the
cells. Moreover, co-delivery of 5’DFUR and DOX or SN-38 greatly enhanced the
cell death. Development of similar prodrug nanocarrier show potential for
enhancing the effectiveness of gene-directed enzyme prodrug therapy.
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CHAPTER 5: DEVELOPMENT OF ANTIPHAGOCYTIC CD477$**(' 32/<0(5,& 0,&(//(6 72 7$5*(7 Įvȕ3 INTEGRINBEARING TUMOR CELLS5
5.1.

ABSTRACT

Methoxy(polyethylene glyocol) (MPEG) was used as the initiator in ring-opening
SRO\PHUL]DWLRQRIİ-caprolactone to form hydrophobic MPEG-polycaprolactone,
which was then grafted to hydrophilic cationic polymeric polyethyleneimine to
form amphiphilic copolymers for the preparation of stable micellar nanoparticles.
The formed polymeric micelles were biotinylated via the interaction of biotin/EDC
with the amines on cationic polymers. CD47-streptavidin (extracellular domain of
self-marker CD47) fusion protein was expressed in BL21(DE3) bacteria and then
the crude protein used directly. Through biotin-streptavidin affinity, CD47 was
bound to biotinylated polymeric prodrug micelles and showed antiphagocytic
efficacy when CD47-tagged polymeric micelles were exposed to J774A.1
macrophages. Since CD47 is not only an antiphagocytic ligand but also an
LQWHJULQDVVRFLDWHGSURWHLQLWFDQEHHPSOR\HGWRWDUJHWLQWHJULQĮvȕ3, which is
overexpressed on tumor-activated neovascular endothelial cells. In this study,
CD47-tagged polymeric prodrug micelles were employed to treat two cells lines
-RQHH[SUHVVLQJLQWHJULQĮvȕ3 DQGRQHZLWKRXWLQWHJULQĮvȕ3 expression. Results
show that functionalized polymeric micelle drug carriers were successfully
WDUJHWHGWRLQWHJULQĮvȕ3 by using CD47 as a targeting moiety.
5.2.

INTRODUCTION

Drug delivery carriers have the potential not only to treat but also diagnose many
diseases. However, they still lack in complexity of natural particulates. Red blood
cells, for example, exhibit all of the traits researchers want for their carriers: they
possess a small size, flexibility and ability to evade the immune system for up to
5

The material contained in this chapter is planned for publication in ACS Biomaterials.
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4 months [1]. In 2000, Oldenborg et al., reported that CD47 functioned as a
marker of self on red blood cells [2]. It was found that as a red blood cell ages,
CD47 expression levels do indeed decrease [3]. Moreover, it has been shown
that CD47-streptavidin (CD47-SA) fusion protein endowed antiphagocytic effect
to perfluorocarbon-based oxygen carriers [4]. Furthermore, since CD47 is an
integrin associated protein [5]LWPLJKWEHHPSOR\HGWRWDUJHWLQWHJULQĮvȕ3, which
is overexpressed on tumor-activated neovascular endothelial cells and
unexpressed on mature quiescent ones lined in blood vessels [6]. In this study,
CD47-SA was bound on to biotinylated micelle carriers and the antiphagocytic
SURSHUWLHVDVZHOODVDELOLW\WRWDUJHWĮvȕ3 integrin examined.
To this end, polymeric micelles were chosen as a model system for this
study. Here, methoxy(poly ethylene glycol) (MPEG) possessing a hydroxyl group
was used as the initiator of ɸ-caprolactone to obtain MPEG-SRO\ İ-caprolactone)
(MPEG-PCL). PCL, is widely used as a core-forming hydrophobic segment
because of its biodegradablility and biocompatibility [7-9]. To form amphiphilic
block copolymers for micelle preparation, hydrophilic polyethylenimine (PEI) was
grafted onto hydrophobic MPEG-PCL. PEI is widely used for nonviral gene
delivery [10-12]. Our results show that CD47-tagged polymer micelles can evade
phagocytosis for up to 6 h. Moreover, carriers targeted to cells bearing high levels
RILQWHJULQĮvȕ3 had much higher uptake of micelles after 4 h of treatment.
5.3.
5.3.1.

MATERIALS AND METHODS
Materials

N,N’-GLF\FORKH[\O FDUERGLLPLGH '&&  İ-CL, pyrene, and succinic anhydride
were purchased from Acros Organics (Geel, Belgium). Sn(Oct)2, CDCl3 with 1%
tetramethylsilane (TMS), deuterated dimethyl sulfoxide (DMSO-d6), dimethyl
sulfoxide (DMSO), tetrahydrofuran (THF), dichloromethane (DCM), methanol, 2propanol, hexane, toluene, MPEG (MW = 350), PEI (MW = 10K), Biotin, and 1Ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) were all purchased from
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Sigma-Aldrich (St. Louis, MO). Ethyl ether was purchased from J.T. Baker
(Austin, TX). N-Hydroxysuccinimide (NHS) was purchased from Alfa Aesar (Ward
Hill, MA). Acetone was purchased from Pharmco-AAPER (Shelbyville, KY).
Pyridine and hydrochloric acid (HCl) were purchased from EMD (Philadelphia,
PA). Sodium chloride (NaCl) and magnesium sulfate were purchased from
Showa (Tokyo, Japan). All reagents were used as received without further
purification.
5.3.2.

Synthesis of MPEG-PCL-PEI

MPEG PJ ZDVZHLJKHGDQGPL[HGZLWKİ-CL (2.25 mL) under a sonication
bath for 5 min at room temperature. Sn(Oct)2 ZWRIİ-CL) was then added
into the mixture. The entire solution was placed into a 3-necked round-bottom
flask. The system was purged with nitrogen and immersed in an oil bath at 140oC
for 24 h. The crude product was cooled to room temperature, dissolved in DCM,
and precipitated by cold methanol. The product was then vacuum dried by a
rotary evaporator at 40oC.
MPEG-PCL (0.5 mmol) and succinic anhydride (1 mmol) were weighed
and dissolved in toluene in a 3-necked round-bottom flask. One mmol pyridine
was added and the solution was reacted under nitrogen at 70oC for 48 h. The
product was then precipitated by cold hexane, and spun down. The pellet was redissolved in DCM and washed twice each with 10% (v/v) HCl and saturated NaCl
solution. The organic phase was isolated and dried with magnesium sulfate then
filtered. The carboxylated MPEG-PCL was recovered by precipitation in cold
hexane and then vacuum dried by rotary evaporation at 40oC.
MPEG-PCL-COOH (0.54 mmol) and NHS (2.7 mmol) were weighed and
mixed in 15 mL DCM, and then DCC (2.7 mmol) was added. The reaction was
run under a nitrogen environment at room temperature for 24 h. The precipitated
byproduct 1,3-dicyclohexylurea was removed by vacuum filtration. The filtrate
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was added into 35 mL diethyl ether and cooled to 4oC for 4 h to precipitate MPEGPCL-NHS. The precipitate was collected by centrifugation at 3,500 rpm for 5 min,
washed with 2-propanol and solvent removed by rotary evaporation at 40oC.
MPEG-PCL-NHS (10 mg) and PEI (MW = 10K) (10 mg) were weighed and
dissolved by 20 mL DCM in a round-bottom flask. The flask was purged with
nitrogen and the solution was stirred for 24 h. The solution was then dialyzed
(MWCO = 6-8 kD, Spectra/Por, Rancho Dominguez, CA) against pure DCM to
remove remaining PEI. MPEG-PCL-PEI was recovered by rotary evaporation at
40oC.
5.3.3.

Preparation of polymeric micelles

MPEG-PCL-PEI were formed by adding 10 mg of MPEG-PCL-PEI amphiphilic
polymer, to 2 mL acetone and dissolving under bath sonication. The solution was
then added dropwise to 10 mL deionized water under bath sonication. Acetone
was removed by rotary evaporation and the final solution was collected by filtering
through a 0.45 μm filter.
5.3.4.

Size and zeta potential measurements

The average particle size of polymeric prodrug micelles was determined by a
dynamic light scattering (DLS) instrument (Zetasizer Nano ZS, Malvern
Instruments, United Kingdom) equipped with a red laser at a wavelength of 633
nm and scattering angle of 90o at 25oC. The zeta potential of the micelles
dispersed in deionized water was determined with a zeta potential analyzer
(Zetasizer Nano ZS).
5.3.5.

Biotinylation of polymeric micelles

EDC was used to activate biotin for subsequent reaction with polymeric micelles.
Here, 1 mg Biotin and 1 mg EDC were dissolved in PBS for 15 min. Biotin/EDC
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mixture was then added to MPEG-PCL-PEI micelles (1 mg mL-1) and mixed. After
30 min, 10 μL FITC (5 mg mL-1 in DMSO) was added to the micelle/biotin/EDC
mixture. After 3 h, the biotinylated micelles were purified by dialysis (MWCO = 68 kD, Spectra/Por, Rancho Dominguez, CA) to remove excess biotin/EDC and
FITC.
5.3.6.

Amplification and expression of CD47-SA fusion protein

Mouse CD47 cDNA clone pME18S-FL3 CD47 was obtained from Dr. Stanley
Tahara at University of Southern California. The extracellular domain of CD47
was amplified from full-length mouse CD47 cDNA by polymerase chain reaction
(PCR) with the sense primer 5’-GGCTCATGACAGCTCAACTACTGTTTAGT-3’
and the antisense primer 5’-GCGGGATCCTTTTCATTTGGAG-3’. The core
streptavidin coding region was amplified by PCR from pSTE2-215 (yol), which is
single chain antibody fused to core streptavidin, using PCR primers 5’CGGATCCTGGTGCTGCTGAAGCAGGTATCACCT-3’

and

5’-

GCTCGAGGGAGGCGGCGGACGG-3’. Core streptavidin was inserted between
BamHI and XhoI site of pET20b (Novagen) to give pMA005. The extracellular
domain of CD47 PCR product was inserted between the NcoI and BamHI site of
pMA005 to yield pMA006.
DH5ĮFRPSHWHQWFHOOV (Invitrogen) were used for plasmid amplification of
pMA006. Briefly, 2 μL of plasmid solution was mixed with 100 μL competent cells.
After incubating on ice for 30 min cells were heat-shocked for 45 sec in a 42oC
water bath. Cells were added to 0.9 mL SOC medium and agitated in a shaker
incubator at 37oC for 1 h. Cell suspension was added to agar plated containing
50 μg mL-1 ampicillin and grown overnight. For CD47-SA expression, BL21(DE3)
cells (Invitrogen) were used. Here, 5 μL pMA006 was added to 100 μL BL21(DE3)
cells, incubated on ice for 30 min and then heat-shocked for 30 sec in a 42oC
water bath. The cells were added to 0.250 mL SOC medium and then agitated in
a shaker incubator at 37oC for 1 h. Cells were then spread on agar plates
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containing 100 μg mL-1 ampicillin and incubated overnight at 37oC. One colony
was chosen from the plate and grown until they reached mid-log (OD = 0.4). For
induction, 1 mM isopropylthioglaactoside (IPTG) was added. Protein was purified
from bacterial lysated by standard methods and then used directly for subsequent
studies.
5.3.7.

Quantification of CD47-SA binding

The amount of biotin conjugated onto the micelle surface was determined through
the spectrophotometric method proposed by Green et al [13]. The basis of this
assay is that the dye HABA binds to avidin, but is stoichiometrically displaced by
biotin. Briefly, 10 mL DI water was added to HABA/avidin reagent (Sigma). In a
96-well plate, 90 μL HABA/avidin reagent and 10 μL sample was added. The
absorbance at 500 nm was then read. Using the beer lambert law, the amount of
biotin/micelle particle was determined:
୧୭୲୧୬
୧ୡୣ୪୪ୣ ୮ୟ୰୲୧ୡ୪ୣୱ

=

οఽఱబబ ౣౣౢ
యరబబబכౢ ౣౢ
ౣౙౢౢ ౦౨౪ౙౢ౩
ౣౢ

(1)

:KHUH $ LV WKH DEVRUEDQFH RI WKH VDPSOH DW  QP İ LV WKH DEVRUSWLYLW\ RI
extinction coefficient, l is the cell path length expressed in cm and C is the
concentration of the sample expressed in molarity. The amount of biotin
calculated was then assumed to directly relate to the amount of CD47-SA bound
onto the particle surface.
5.3.8.

Macrophage studies

Murine macrophage cell line J774A.1 (ATCC) was used for phagocytosis assays.
Cells (106) were plated in 6-well plates with 2 mL Dulbecco’s modified Eagles’
medium (DMEM, Corning Cellgro, Manassas, VA) supplemented with 10% fetal
bovine serum (FBS, Atlanta biologicals, Flowery Branch, GA) and 1% penicillinstreptomycin (Sigma) and incubated at 37oC in 5% CO2 balanced with humidified
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air for 24 h.. Macrophage cells were then treated with CD47-tagged polymeric
micelles and biotinylated polymeric micelles. The cells were imaged under Leica
DMI3000 B microscope equipped with a Leica DFC360 FX camera (Leica
Microsytems, Wetzlar, Germany) at 2 h, 4 h and 6 h. After each time point, cells
were washed with PBS and then trypan blue solution (2 mg mL-1) was added to
quench outside fluorescence and imaged again. Cells were then used directly for
flow cytometry analysis (BD Accuri C6).
5.3.9.

Integrin targeting

PC3 cells (ATCC), which overexpress integrin Įvȕ3, and BHK21 cells, which have
low integrin Įvȕ3 expression, were used for integrin targeting studies. Cells (106)
were plated in 6-well plates with 2 mL Dulbecco’s modified Eagles’ medium
supplemented with 10% fetal bovine serum and 1% penicillin-streptomycin and
incubated at 37oC in 5% CO2 balanced with humidified air for 24 h. Cells were
then treated with CD47-tagged polymeric micelles and biotinylated polymeric
micelles. After 2 h and 4 h, cells were washed and 2 mg mL-1 trypan blue solution
was added to quench outside fluorescent. Cells were imaged by fluorescent
microscopy (Leica).
5.4.

RESULTS AND DISCUSSION

5.4.1.

Characterization of polymeric micelles

Figure 5.1 (A-D), shows the synthesis of MPEG-PCL-PEI copolymer. Size and
zeta analysis of polymeric prodrug micelles can be seen in Figure 5.2. An average
size of 153.2 nm and zeta potential of 43.4 mV was seen for MPEG-PCL-PEI
micelles.
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Figure 5.1. Synthetic scheme of (A) MPEG-PCL, (B) MPEG-PCL-COOH, (C)
MPEG-PCL-NHS, and (D) MPEG-PCL-PEI

Figure 5.2. Size and zeta analysis of MPEG-PCL-MPEG.
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Figure 5.3. Synthetic scheme of biotinylation and fluorescence of micelles.

After synthesis of the copolymer, and self-assembly into micellear
nanoparticles, biotin was added through EDC crosslinking (Figure 5.3). Here,
biotin was activated by EDC and then allowed to bind onto the micelle surface for
30 min before the addition of FITC for fluorescence. Biotin on the surface of
polymeric micelles was measured using the HABA/avidin assay. A solution of
HABA/avidin shows absorbance a 500 nm as avidin is displaced by the biotin
which is bound on the micelle surface, the absorbance at 500 nm will decrease.
As seen in Figure 5.4 (A), as the amount of biotinylated micelle added to the
assay was decreased (0.5 dilution), the absorbance at 500 nm decreased. In
contrast, after binding CD47-SA to the biotinylated micelle, no absorbance
change was observed (Figure 5.4 B). This tells us two things, first we have
successful binding of CD47-SA to bintinylated micelles and second, that the
CD47-SA amount is sufficient to bind to all of the biotin molecules on the micelle
surface.
Using the Beer Lambert law, we were able to quantify the amount of biotin
and therefore CD47-SA bound onto the micelle surface. Using equation 1, we
found that the amount of biotin/micelle particle was equal to 2.25 x 10-17 mol
Biotin/ micelle particle. After multiplying by Avagadro’s number, we found that the
concentration of biotin on the surface of the micelles was 1.4 x 107 biotin
molecules/micelle particle. Despite the fact that biotin and streptavidin have four
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potential binding sites, CD47-SA at 26 kDa is much larger than one biotin
molecule. Therefore because of steric hindrance we believe that for every one
biotin molecule on the micelle surface, one molecule of CD47-SA will bind.
Therefore, the amount of biotin molecules on the micelle surface will be equal to
the amount of CD47-SA bound on the micelle surface.

Figure 5.4. HABA/avidin assay. If biotin is present, HABA will be displaced from
avidin resulting in a decrease of absorbance at 500 nm. (A) biotinylated micelles, and
(B) CD47-tagged micelles.

5.4.2.

Antiphagocytic effect

To observe the antiphagocytic effect endowed onto micelle particles by CD47SA, cell studies were conducted. As shown if Figure 5.5, cells treated readily
phagocytized biotinylated micelle particles while CD47-tagged particles showed
little uptake. While little difference was seen after 2 h of treatment (most likely
due to the small size of micelle particles) (Figure 5.5 A and B), 4 h and 6 h clearly
show more fluorescence in biotinylated micelles (Figure 5.5 C and E) than in
CD47-tagged micelles (Figure 5.5 D and F).
The 6 h sample, which by fluorescent imaging showed the biggest
difference in particle uptake by macrophages was run on flow cytometry. As can
be seen from Figure 5.6, a shift in the mean fluorescent intensity of biotinylated
and CD47-tagged micelles was seen. The mean fluorescence intensity of
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biotinylated and CD47-tagged micelles was quite different at 3628.33 and
2325.60, respectively.

Figure 5.5. Effect of CD47 on micelle uptake by J774A.1 cells. (A) 2 h treatment with
biotinylated micelles, (B) 2 h treatment with CD47-tagged polymeric micelles, (C) 4 h
treatment with biotinylated micelles, (D) 4 h treatment with CD47-tagged polymeric
micelles, (E) 6 h treatment with biotinylated micelles, and (F) 6 h treatment with
CD47-tagged polymeric micelles.

Figure 5.6. Flow cytometry analysis of J774A.1 macrophages after treatment with
biotinylated and CD47-tagged micelles for 6 h.
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5.4.3.

Integrin targeting

Since CD47 is an integrin associated protein [5], it might be employed to target
LQWHJULQĮvȕ3, which is overexpressed on tumor-activated neovascular endothelial
cells and under expressed on mature quiescent ones lined in blood vessels [6].
In the previous section, we have shown that CD47 serves as an antiphagocytic
ligand, to show that CD47 can also be used to target drug carriers, PC3 cells
which show high levels of integULQĮvȕ3 were treated with our CD47-tagged micelle
carriers. As can be seen in Figure 5.7 FHOOV ZLWK ORZ Įvȕ3 expression (BHK)
despite having micelle carriers surrounding the cells (Figure 5.7 A and B) showed
very little uptake of micelle carriers after trypan blue treatment (Figure 5.7 C and
D). In contrast, PC3 cells showed a much higher uptake level of micelle carriers
after trypan blue treatment (Figure 5.8 C and D).

Figure 5.7. Integrin targeting to BHK21 FHOOVZKLFKKDYHORZH[SUHVVLRQRIĮvȕ3
integrin. BHK21 cells were treated with CD47-tagged micelle carriers for 4 h. (A)
Fluorescent image, (B) overlay of bright field and fluorescent image, (C)
fluorescent image after trypan blue treatment to quench outside fluorescent, and
(D) overlay of bright field and fluorescent image.
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Figure 5.8. Integrin targeting to PC3 cells which have high H[SUHVVLRQ RI Įvȕ3
integrin. PC3 cells were treated with CD47-tagged micelle carriers for 4 h. (A)
Fluorescent image, (B) overlay of bright field and fluorescent image, (C)
fluorescent image after trypan blue treatment to quench outside fluorescent, and
(D) overlay of bright field and fluorescent image.

5.5.

CONCLUSIONS

In this study, biotinylated polymeric micelles were successfully synthesized.
Moreover, CD47-SA was conjugated onto the micelle surface via biotin/SA
affinity. Macrophages treated with CD47-tagged micelles revealed and
increased antiphagocytic effect as well as increased the uptake into cells with
KLJKĮvȕ3 expression. These results indicated that CD47 can be utilized not
only as an antiphagocytic ligand but also serve to target drug carriers onto
abnormal eQGRWKHOLDOFHOOVEHDULQJKLJKOHYHOVRIĮvȕ3 and thereby block tumor
angiogenesis. CD47-tagged nanocarriers could potentially be developed
enhanced anticancer therapy due to their immune evasion and targeting
capabilities.
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CHAPTER 6: SUMMARY AND FUTURE DIRECTIONS
6.1.

THESIS CONCLUSIONS AND SUMMARY OF FINDINGS

Gene-directed enzyme prodrug therapy is a promising approach. Some major
problems remain to be solved before enzyme/prodrug strategies can become a
routine therapeutic approach, largely due to inefficient drug/gene delivery. The
findings in this thesis outlines an innovative approach for delivery of prodrug,
gene and cytotoxic drug to malignant cells.
Prodrugs acyclovir (ACV), ganciclovir (GCV), and 5-doxifluridine (5’DFUR)
were used as the sole initiators in the polyPHUL]DWLRQ RI İ-FDSURODFWRQH İ-CL).
The prodrug-tagged poly(caprolactone) PCL was then grafted with hydrophilic
polymers for form amphiphilic block copolymers. Synthesis of prodrug-tagged
polymeric micelles was followed via standard analytical means including 1H NMR,
FTIR, GCP, size and zeta analysis, and CMC. Our results indicate that prodrugtagged micelles between 100-200 nm can be synthesized. Studies with ACV
confirmed bioavailability of prodrug-tagged polymeric micelles up to a
concentration of 500 mg mL-1. Cytotoxity studies with GCV confirmed that a onestep GDEPT process is a feasible anticancer therapy approach. It was found that
4.5 μg of HSV-TK gene plasmid complexed onto GCV-PCL-chitosan micelles
was sufficient to decrease cell viability to 52%. This was a 25% increase in cell
death compared to the conventional two-step delivery of gene, followed by
prodrug. Cytotoxicity studies with 5’DFUR, confirmed that suicide gene/prodrug
pairs, in conjunction with treatment from other chemotherapy drugs, can
substantially increase cell toxicity.
Furthermore, in an effort to develop multifunctional polymeric micelle
carriers which can evade the immune system and target to tumor cells, CD47-SA
was tagged onto the micelle surface via biotin/SA affinity. Our studies indicate
that CD47-tagged micelle carrier can evade macrophage phagocytosis for up to
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K,QDGGLWLRQZKHQWDUJHWHGWRFHOOVZKLFKXQUHJXODWHGLQWHJULQĮvȕ3, micelle
uptake was increased considerably.
6.2.

FUTURE DIRECTIONS
This thesis has shown the feasibility of polymeric micelle carriers for the

delivery of prodrug/gene and prodrug/cytotoxic drugs to tumor cells. Further work
can be conducted to deliver all three (prodrug, gene and cytotoxic drug)
simultaneously to malignant cells. Based on the results established here,
anticancer therapy would be enhanced by a GDEPT system optimized for onestep delivery.
Moreover, this thesis has shown that extracellular targeting and
antiphagocytosis can be achieved by binding CD47-SA onto the micellar surface.
It would be of interest, especially in the case of one-step delivery, to use a nuclear
localization sequence (NLS) to target the micelle carrier or DNA to the nucleus.
A NLS is an amino acid sequence that tags a protein for import into the cell
nucleus by nuclear transport [1]. For our proposed one-step delivery method, the
DNA bound onto chitosan is delivered through passive diffusion. The application
of NLS peptides for nonviral gene transfer has been widely investigated [2-4].
Therefore, the addition of an NLS onto the DNA or micelle carrier would allow for
active targeting which should enhance gene efficiency greatly.
The work conduced in this thesis also has the potential to be applied to
other GDEPT systems, including but not limited to, cytosine deaminase (CD)/5fluorocytosine (5-FC). 5-FC is one of the main anticancer drugs used to treat
colon, pancreatic and breast cancers. Similar to 5’DFUR, 5-FC is converted to 5FU by CD. CD, unlike TP, has little cellular activity in humans and therefore
increasing tumor cell proliferation is not a fear. Moreover, CD/5-FC has one of
the strongest bystander effects demonstrated [5] and has shown more effective
than the HSV-TK/GCV system in the treatment of renal and colorectal cancers
[6, 7]. In addition to enhanced anticancer effectiveness, ring-opening
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SRO\PHUL]DWLRQRIİ–CL by 5-FC would be initiated by an amine group, rather than
a hydroxyl group as shown in the currently discussed prodrugs. Amine initiation
has several advantages because the prodrug will not be cleaved as easily from
the micelle carrier therefore allowing for extended release of the drug (see Figure
6.1) and increased activation time of the gene in a one-step delivery system.
Oledzka et al. previously showed that amino acids can be used as initiators RIİ–
CL and L,L-lactide polymerization [8]. Therefore, it is reasonable that 5-FC can
be used to created prodrug-tagged polymeric micelles. Based on the drug release
profile for 5-FC, it can be seen that compared to the previously used
gene/prodrug pairs discussed in this thesis, the release profile of 5-FC is
extensively enhanced. Here, it takes up to 12 h before 50% of the prodrug is
released. Moreover, if we model the release data using the Langmuir model, we
get a dissociation constant (Kd) of 7.77, this shows a much stronger association
then any of the previously discussed gene/prodrug pairs.

Accumulated release (%)

120
100
80
60
40
20
0
0

10

20

30

40

50

60

Time (h)
Figure 6.1. In vitro drug release profile of 5-FC from 5-FC-PCL-MPEG in PBS at
37oC.
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